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Abstract   
Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome caused by germline 
mutations in the tumour suppressor gene CDH1, which encodes the cell-cell adhesion protein 
E-cadherin. Mutations in CDH1 lead to increased proliferation, invasiveness and loss of cell 
polarity. Patients with germline CDH1 mutations have a 70% lifetime risk of developing 
gastric cancer. Female carriers also have a 42% lifetime risk of developing lobular breast 
cancer.  
 
The current optimal treatment for HDGC is a prophylactic gastrectomy as surveillance 
through endoscopy is imperfect and tumours can be discovered at a late stage. This project 
aims to utilise the synthetic lethal (SL) approach to find a chemopreventative treatment for 
HDGC. The SL approach aims to manipulate cell viability by exploiting the relationships 
between related genes. Synthetic lethality is a gene relationship in which an inactivation of 
either of two genes alone allows cell survival, however when both are inactivated it leads to 
cell death.  
 
Previous work within the laboratory has identified potential SL targets for CDH1 via high 
throughput drug screening. This was carried out in an isogenic pair of non-tumourigenic 
breast epithelial MCF-10A cell lines, one lacking CDH1 function. This identified histone de-
acetylase inhibitors (HDACi) and statins as promising SL therapies for HDGC as they can 
selectively inhibit growth of CDH1-/- cells. Epigenetic changes, such as histone acetylation 
and deacetylation, modify expression patterns and are linked to cancer progression. Statins 
are widely used, well tolerated drugs that lower cholesterol levels and impact on plasma 
membrane organisation.  
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This project has validated successful SL compounds from the MCF-10A drug screen in a 
gastric cancer model, using isogenic NCI-N87 CDH1+/+ and CDH1-/- cell lines. Promising 
compounds that have shown the best SL effect in 2D cell culture models, were then analysed 
for clinical trial data to find drugs that have minimal adverse effects. The compounds with 
minimal side effects and strong SL relationship with CDH1, were then assessed in a gastric 
organoid model of HDGC. This organoid model called the air-liquid interface (ALI) model, 
is a 3D representation of the gastric gland and contains all gastric cell lineages. As such it is a 
more accurate pre-clinical model for drug screening than 2D cultures. A second organoid 
model, the submerged model, was also further developed as it is a higher throughput model 
and will be more efficient for future drug compound testing.  Mocetinostat, the compound 
identified to have the best synthetic lethal effect, will now undergo further preclinical testing 
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°C – Degrees Celsius  
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μL – Microlitre 
μm – Micrometre  
μM – Micromole(s) per litre 
2D – Two dimensional 
3D – Three dimensional 
ALI – Air liquid interface 
CDH1 – E-cadherin 
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CO2  - Carbon dioxide 
CTCL – Cutaneous T-cell lymphoma 
DAPI – 4′,6-diamidino-2-phenylindole 
DGC – Diffuse gastric cancer 
DMEM-F12 – Dulbecco’s modified Eagle’s medium and F12 medium  
DMSO – Dimethyl sulfoxide 
EMT – Epithelial-mesenchymal transition 
FBS – Foetal bovine serum 
FITC - Fluorescein isothiocyanate 
HDACi – Histone deacetylase inhibitor  
HDAC – Histone deacetylase  
HDGC – Hereditary Diffuse Gastric Cancer 
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HMG-CoA – 3-hydroxy-3-methylglutaryl-coenzyme A  
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MFB11 – Myofibroblast cell line  
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mM – Millimole(s) per litre 
PARP - Poly (ADP-ribose) polymerase 
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Chapter 1: Introduction  
 
1.1 Gastric cancer  
Gastric cancer has the fifth highest incidence of all cancers worldwide, and the third highest 
mortality rate [2]. 783,000 deaths were due to gastric cancer in 2018, this is 75% of the 
number of new cases diagnosed that year [3]. The high mortality rate is due to gastric cancer 
being: i) relatively asymptomatic in mid stages and ii) a multifactorial disease with many 
environmental and genetic risk factors. This culminates in late stage detection of gastric 
cancer and poor prognosis for patients with a 5-year survival rate of 10% [4].  
 
Gastric cancer rates vary with geographical location, with the highest incidence of 22.4 cases 
per 100,000 people in East Asia, while the lowest incidence occurs in Western Europe with 
an incidence of 5.8 in 2018 [3]. This regional variance is due to different exposures to 
environmental risk factors, like high salt diets, smoking, obesity and Helicobacter pylori (H. 
pylori) infection rates [5, 6].  H. pylori usually presents as an asymptomatic infection with 
around 44.3% of the population being carriers [7] and around 5% of these carriers will 
develop gastric cancer, making it the most penetrant environmental risk factor [8]. The 
incidence of gastric cancer worldwide is two-fold higher in males than females [3]. Studies 
show that oestrogen may have a protective effect in H. pylori induced gastric cancer, leading 
to the lower incidence in females [9].   
 
The global incidence of gastric cancer has decreased overtime due to the mitigation of 
environmental risk factors through improved food preservation, diet and reduced rates of H. 
pylori infection [10, 11]. However, there are also genetic risk factors for gastric cancer, for 
example mutations in the CDH1 gene. Genetic risk does not fluctuate like environmental risk 
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factors, therefore the incidence of gastric cancer in the younger population has stayed 
constant [12].  
 
1.1.1.Gastric cancer in New Zealand  
New Zealand (NZ) is a relatively low incidence country, with mortality rates of less than 4 
per 100,000 people, compared to over 20 in countries in East Asia [6, 7, 13, 14]. In NZ, the 
rates of gastric cancer are disproportionately high in the Māori and Pacific populations, with 
a three- to six-fold increase in the rate of gastric cancer compared to NZ European 
populations [8]. A study by Ellison-Loschmann et al. showed that the NZ Māori population 
had an increased exposure to environmental risk factors, for example rates H. pylori infection 
and smoking. This may partially explain the increased prevalence of gastric cancer [15]. 
Similar to worldwide statistics, the incidence and mortality rate of gastric cancer in NZ is 
decreasing [16].    
  
1.1.2.Histological subtypes of gastric cancer   
There are two primary histological subtypes of gastric adenocarcinoma, intestinal- and 
diffuse-type, as defined by the Lauren classification. There are also mixed histologies of the 
two subtypes, and some adenocarcinomas are not able to be defined within the Lauren 
classification [17]. Intestinal-type gastric cancer presents with intestinal metaplasia, well-
defined gastric ducts, inflammatory infiltrate and larger tumour cells with enlarged 
pleomorphic nuclei (Figure 1A) [13, 17]. In contrast, diffuse-type consists of isolated tumour 
cell groups lacking glandular structure, partially due to the lack of cell-cell junctions [14, 18]. 
Diffuse-type is often comprised of signet ring cells. Signet ring cells are large cells with 
mucous filled vacuoles that push the nucleus to the periphery (Figure 1B). However, signet 
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ring cells are not limited to diffuse-type adenocarcinomas and can be found in intestinal-type 
lesions, but less frequently [13]. 
 
Figure 1: Primary gastric cancer histological subtypes according to Lauren classification. 
 A: Intestinal-type gastric cancer with defined gastric ducts B. Diffuse-type gastric cancer 
with lack of glandular structure and large numbers of signet ring cells (Arrow pointing to a 
signet ring cell). Excerpt from [19]. 
 
 
Another key histological classification system is the World Health Organisation (WHO) 
classification which defines 4 major gastric cancer subtypes and many uncommon variants. 
Tubular adenocarcinoma is the most common major subtype, presenting as large polyploid 
branching tubules surrounded by nuclear and inflammatory debris. Papillary adenocarcinoma 
subtype consists of epithelial projections held together by a fibrovascular centre. Mucinous 
adenocarcinoma is the third WHO subtype, accounting for 10% of gastric carcinomas. 
Mucinous adenocarcinoma is histologically characterised by glandular or clustered cells, 
surrounded by extracellular mucous pools, which make up over 50% of the tumour mass. 
Lastly, signet ring cell carcinoma, or poorly cohesive subtype, contains a mixture of signet 
ring cells and other non-signet ring cells. These can form irregular cell structures similar to 
glands and micro-trabeculae[20]. The signet ring cell carcinoma subtype correlates with the 
Lauren classification of diffuse-type gastric cancer [20] and the Lauren classification of 
intestinal-type correlates with the papillary, tubular and mucinous WHO subtypes [21].  
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The Cancer Genome Atlas (TCGA) has developed a molecular classification system, 
identifying four molecular subtypes; Epstein-Barr virus (EBV) infected tumours, tumours 
with microsatellite instability (MSI), genomically stable (GS) tumours and tumours with 
chromosomal instability (CIN) [22]. The CIN molecular subtype comprised 50% of the total 
samples and presented with aneuploidy, gene amplifications and TP53 mutations. The 
histology of the CIN subtype showed glandular structure and correlated with the Lauren 
intestinal-type gastric cancer. The Lauren diffuse-type histology was seen in the TCGA GS 
subtype, which composed 20% of the total samples and had the largest proportion of CDH1 
mutations [23]. However, this classification of histological (Lauren and WHO) or molecular 
(TCGA) subtype is currently a descriptive tool that is unable to provide any prognostic 
information. Understanding of the molecular subtypes is essential for the development of 
targeted molecular therapies, but histological or molecular subtype currently has no impact 
on treatment stratification and all gastric cancers are treated uniformly [22, 23].  
 
1.2. Hereditary Diffuse Gastric Cancer  
1-3% of all gastric cancer cases are due to a genetic predisposition [24]; Hereditary Diffuse 
Gastric Cancer (HDGC) makes up one third of this group [24]. HDGC was first discovered in 
1998 in a Māori whānau with a family history of gastric cancer. These family members 
presented with diffuse-type gastric cancer, and suffered a mortality age ranging from 14-40 
years old, in contrast with the NZ mean age of over 60 years [25]. A mutation in CDH1 was 
found to be the cause of the hereditary gastric cancer [25]. In NZ Māori, 13% of all diffuse 
gastric cancer cases are due to a mutation in CDH1, this is three to five fold higher than that 
of the NZ European population. CDH1 mutations are therefore an important contributor to 
the increased rate of gastric cancer in the Māori population [26]. 
 14 
HDGC is an autosomal dominant syndrome caused by germline mutations in the CDH1 gene 
encoding the cell adhesion protein E-cadherin. Mutations in CDH1 lead to a 70% lifetime 
risk of developing diffuse gastric cancer in men and 56% for women [27]. The lifetime risk 
of developing lobular breast cancer also increases to 42% for women [27]. The histological 
subtype of HDGC is the Lauren diffuse-type, with pagetoid spread (proliferation of cells 
between the epithelia and basement membrane) of signet ring cells amongst the normal 
mucosal layer of the gastric epithelia [27]. The discovery of the molecular mechanism has led 
to early diagnosis of more people and an understanding of the disease [14, 25, 28, 29] but no 
prophylactic drug treatments currently exist. Further investigation into the molecular 
mechanism therefore needs to occur to improve treatment options for patients.  
 
1.2.1.  E-cadherin 
The CDH1 gene encodes the cell adhesion protein E-cadherin, which belongs to the cadherin 
superfamily of transmembrane glycoproteins[12, 30, 31]. E-cadherin has an important role in 
cell structure [30] as it is an integral part of the adherens junction (Figure 2). Extracellular 
domains of adjacent E-cadherin molecules form homodimers, allowing connection to the 
intracellular actin cytoskeleton between adjacent cells (Figure 2). This connection of E-
cadherin to the intracellular actin cytoskeleton occurs through alpha and ß-catenin molecules 
[32]. The adherens junction made up of E-cadherin homodimers form dynamic strong bonds 
between neighbouring cells to maintain individual cell structure.  
 
As well as maintaining cellular and tissue structure, the adherens junctions between epithelial 
cells also directs correct cell polarity. This is important for the orientation of the mitotic 
spindle, and the resulting division of daughter cells within the epithelial plane [33]. E-
cadherin is also involved in cellular signalling through interaction with ß-catenin, a key part 
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of the WNT signalling pathway. E-cadherin holds ß-catenin at the cytoskeleton, preventing 
its translocation to the nucleus where it activates gene transcription [32].  
 
 
1.2.1.1. Pathogenic E-cadherin  
CDH1 mutations leading to inactivation of E-cadherin are associated with increased 
invasiveness and metastasis, abnormal differentiation and proliferation, and loss of both cell 
adhesion and cytoskeletal organisation[34]. This is due in part to the lack of adherens 
junctions and in turn the inability to maintain cell polarity. This allows for mis-alignment of 
the mitotic spindle and mitosis to occur out of the epithelial plane, resulting in increased 
invasion into other tissue and abnormal cell differentiation[33]. Loss of E-cadherin function 
is also a key step in inducing Epithelial to Mesenchymal transition (EMT) which is the 
process where epithelial cells transition towards a mesenchymal cell phenotype. EMT is a 
normal process in embryonic development, however, in cancer, this process is associated 
with increased invasiveness and metastasis [35]. All of these factors mean CDH1 is an 
important tumour suppressor gene in epithelial cells, and loss of CDH1 function leads to 
cancer development [36]. 
Figure 2: Schematic of the adherens junction.  
Adherens junction between two epithelial cells highlighting the E-cadherin homodimer and 
interactions between E-cadherin, ß-catenin and Actin. Adapted from Kobielak et al. [1] 
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1.2.1.2. E-cadherin and HDGC 
A third of all hereditary gastric cancers are due to germline mutations in the CDH1 tumour 
suppressor gene [24]. Germline homozygous loss of function of CDH1 is embryonically 
lethal [37], so HDGC patients have one mutated CDH1 allele and have heightened sensitivity 
to mutation or epigenetic silencing of the second wild type CDH1 allele, triggering the 
development of gastric cancer [38]. Mutation of the second CDH1 allele leads to the loss of 
E-cadherin, causing all the pathogenic effects discussed previously: loss of cell adhesion, loss 
of cell polarity, increased proliferation, invasion into mucosal tissue, leading to the formation 
of signet ring cell carcinomas and HDGC. There have been over 155 different germline 
CDH1 mutations identified, 126 of which being pathogenic and the remainder unclassified 
[39]. These different CDH1 mutations are found throughout the whole gene, with no 
evidence of phenotype-genotype correlation, meaning all CDH1 mutation positive gastric 
cancers are clinically treated the same [39].  
 
1.2.2. Treatment and prevention of HDGC  
Clinical guidelines for the treatment of HDGC have developed from the improved knowledge 
of the syndrome and the role of CDH1 in the penetrance of gastric cancer. Current clinical 
guidelines recommend that patients who fulfil any of the following criteria should undergo 
genetic testing for a pathogenic CDH1 mutation[27].  
- Two cases of gastric cancer in the family, regardless of age, with one confirmed as a 
diffuse subtype gastric cancer. 
- One case of diffuse-type gastric cancer in a family member under 40 years of age. 
- Family history of diffuse gastric cancer and lobular breast cancer, with at least one 
case prior to 50 years of age. 
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After genetic screening, if a pathogenic CDH1 mutation is found, patients have two treatment 
options: endoscopic surveillance or prophylactic gastrectomy. Genetic counselling is also 
provided alongside this process to guide patients through their diagnosis and the risks and 
benefits of each treatment option[12]. 
 
1.2.2.1.Prophylactic Gastrectomy  
If a pathogenic CDH1 mutation is found, the recommended treatment is prophylactic 
gastrectomy, which is the complete resection of the stomach[27].  Prophylactic gastrectomy 
has a large impact on life post-surgery, as there are psychological and physiological impacts 
on the patient that need to be monitored. Patients can suffer from weight loss, nutrient 
deficiencies and loss of appetite[27]. However,  >96% of gastrectomy samples contain 
subclinical signet ring cell carcinomas. These microscopic cancerous lesions would have 
likely developed into advanced diffuse gastric cancer. Therefore, despite the significant side 
effects, prophylactic gastrectomy clearly eliminates the risk of disease progression[40]. 
However, the morbidity associated with prophylactic gastrectomy highlights the need for 
new, less invasive treatments for these families.  
 
1.2.2.2. Endoscopic surveillance 
Another management option is screening or surveillance through endoscopy. Screening 
relates to patients who are not aware of their CDH1 mutation status and surveillance for 
patients who carry a CDH1 mutation, but have decided to not have a prophylactic 
gastrectomy [27]. Detection of HDGC through endoscopy is difficult, as the cancer spreads 
through the mucosal layer under the gastric epithelia, making it hard to detect visually [27]. 
Signet ring cell foci often appear as slight discolouration or pale areas in the epithelia [27]. 
Therefore endoscopy is not the recommended management strategy, as it does not eliminate 
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the risk of developing HDGC. Patients who choose to undergo endoscopic surveillance are 
occasionally only diagnosed at a late stage, when foci become more visible, leading to poor 
prognosis and a less than 10% five year survival rate [4]. The only current effective treatment 
to remove all risk of HDGC is a prophylactic gastrectomy. A chemopreventative therapy 
needs to be developed to reduce the need for gastrectomy and the risk of developing HDGC. 
 
1.3. Synthetic lethality  
Synthetic lethality is an interaction between two genes where as long as one of the two genes 
is functional, the cell is viable. However when function in both genes is lost simultaneously, 
the effect is lethal (Figure 3)[41]. This synthetic lethal (SL) relationship was first discovered 
in Drosophila. Certain chromosomes were ‘synthetic-’ or ‘semi-lethal’ when inherited 
together, producing non-viable offspring, but viable when inherited separately[42]. These 
gene relationships occur naturally to ensure redundancy in cellular processes, so that function 
in a single gene isn’t required for viability, thus reducing the impact of mutation[43]. 
Mutations in tumour suppressor genes in cancer can potentially be exploited through 
targeting of their synthetic lethal partner genes. Using this approach, cancer cells with 
characteristic mutations in tumour suppressor genes can be specifically targeted, leaving 
healthy cells relatively unharmed[44]. This approach has been used in relation to cancers 
with BRCA1/2 mutations. PARP inhibitors induce an SL phenotype and fully inhibit the 





This synthetic lethal strategy provides a promising approach for the development of novel 
therapies for HDGC, through targeting genes in an SL relationship with CDH1. In order to 
develop a chemopreventative drug that mutation carriers are able to take to prevent any 
development of cancer, and reduce the need for what is currently the only effective treatment, 
prophylactic gastrectomy.  
 
1.3.1. Drug candidates for HDGC treatment 
It is predicted that when CDH1 function is lost in HDGC, druggable SL relationships emerge. 
A compound which targets a gene in an SL relationship with CDH1, would affect the 
viability of the CDH1 mutant cells (cancer) allowing non-cancerous cells with healthy CDH1 
to be viable and therefore a potential new HDGC treatment to be developed [47]. Both 
genome-wide siRNA screening and drug screening on E-cadherin-null cell lines and their 
wild-type counterparts have previously been carried out in our laboratory to identify SL 
targets in the genome [47, 48]. The compound screen of 4,057 known drugs in a non-
Figure 3: Schematic of synthetic lethality.  
Gene A and B are synthetic lethal partner genes. When function is lost in one synthetic 
lethal partner gene the cell survives. Loss of function in both synthetic lethal partners genes 
leads to cell death. 
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malignant breast MCF10A CDH1-/- and CDH1+/+ cell line, identified 21 compounds that 
selectively inhibited CDH1-/- cells [47]. Five drugs from two different classes were chosen to 
be further validated as SL compounds in this project, one statin (Atorvastatin) and four 




Statins are inhibitors of HMG-CoA reductase, an enzyme in the mevalonate pathway that 
releases cholesterol into the blood. Atorvastatin also stimulates the liver to increase uptake of 
more lipids, further lowering circulating blood lipid levels. Statins are widely used to lower 
blood cholesterol levels for cardiovascular disease[49]. Atorvastatin represents an ideal 
potential chemopreventative compound, as it is already prescribed to a large proportion of the 
population, with very minor adverse effects [49]. Atorvastatin has also previously been 
shown to selectively inhibit the growth of cell lines with low E-cadherin expression [50]. 
This is likely to be due to reducing cholesterol content in the membrane and altering the 
concentration of cell receptors in lipid rafts [51]. 
 
1.3.1.2. Histone De-acetylase inhibitors  
There are many different classes of HDAC, most commonly found are class I, II and III. 
Class one is involved in death and proliferation pathways in all tissues, while class II is more 
tissue specific. Class III HDAC are involved in transcriptional regulation. Histone 
deacetylase inhibitors (HDACi) block the enzymatic removal of acetyl groups from histones. 
Acetylated histones are transcriptionally active, by blocking de-acetylation with HDACi 
these regions maintain transcriptional activity [52]. De-acetylated histones are common in 
cancer cells and are thought to be a potential mechanism inhibiting expression of tumour 
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suppressor genes such as CDH1, therefore blocking de-acetylation is a promising drug target 
[53]. HDACi’s are relatively well tolerated, with the most common adverse effects being 
fatigue and nausea [54]. Several HDACi’s are FDA approved for cancer treatment [55]. 
HDACi’s have been shown to selectively inhibit the growth of CDH1-/- cells and therefore 
show promise as a potential HDGC therapeutic [47]. In this project, four HDACi were tested: 
Entinostat, Pracinostat, Vorinostat and Mocetinostat. As they were identified in the original 
high throughput screen carried out in this laboratory [47]. 
a) Entinostat, a benzamide HDACi that specifically inhibits class I HDAC’s, which are 
overexpressed in some gastric cancers [56]. Entinostat is currently being assessed in 
phase I and II clinical trials for multiple different cancer types. Proposed mechanisms for 
inhibition of cancer include increased production of reactive oxygen species, apoptosis 
induction and cell cycle arrest [57]. 
b) Pracinostat is a valproic acid HDACi that targets HDACs 1,2 and 4. Clinical trials for 
many solid tumour forms with positive results, including stable disease for greater than 6 
months. A hypothesised mechanism of action is that Pracinostat has anti-angiogenic 
effects within tumour tissue [58]. 
c) Mocetinostat is a new generation synthetic benzamide HDACi which specifically inhibits 
class 1 and 4 HDAC’s. Phase I and II clinical trials with Mocetinostat are ongoing in a 
range of cancers including lymphoma, haematological and solid tumour cancers [59]. 
Common adverse effects include fatigue and GI toxicities, however these have not been 
reported as severe or unmanageable therapeutically. Adverse haematological effects have 
also been observed, however, these were often due to a pre-existing condition [59]. In 
2014, Mocetinostat was approved by the Food and Drug Association (FDA) for the 
treatment of diffuse large cell B lymphoma [60].  
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d) Vorinostat (SAHA) is a pan-HDACi, it inhibits HDAC’s 1 2 and 4 [61]. It has been FDA 
approved for the treatment of cutaneous T cell lymphoma (CTCL). A potential 
mechanism of it anti-tumorigenic effects may involve transcriptional regulation of pro-
growth pathways to stop proliferation[62]. Clinical trials for all the HDACi mentioned 
have shown that common adverse effects are fatigue, nausea and diarrhoea, which are all 
effects that can be managed therapeutically. 
 
1.4. Current models of gastric cancer 
1.4.1. Cell culture model  
Cell culture models of gastric cancer have been developed and characterised, and are 
effectively used as a first step in testing potential therapies for gastric cancer[63]. Cell culture 
is an important first step for the trial of any therapy as it enables for high throughput 
screening in environments that are easy to manipulate compared to more complex models. It 
also allows for clear visualisation of the cellular impact of therapies [63].  However there are 
issues with cancer cell lines as they are highly mutated and will evolve due to the selection 
pressures of cell culture. This creates cell lines that are no longer representative of the cells in 
vivo [64]. Cancer in vivo is also not a 2D structure, and cell culture doesn’t reproduce 
interactions with the extracellular matrix. 2D cell modelling is a useful tool for high 
throughput preliminary data, where results can be further validated in a more complex 3D 
model.  
 
1.4.2. Gastric organoid models 
A more advanced culture model for gastric cancer is gastric organoids. As well as having a 
structure comparable to the gastric gland, a key feature of gastric organoids is that they 
contain all the cell lineages found in the stomach, not just one cell type as in 2D cell 
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culture[65]. They are a lower throughput model than 2D models, and still do not demonstrate 
the full gastric microenvironment, but are an effective intermediate step between 2D cell 
culture and animal models. The first gastric organoids were developed by Barker et al. in 
2010 [65] and since then many models have been developed. This project will utilise two 
models, the Air-liquid interface (ALI) model and the submerged model.  
 
1.4.2.1. Air liquid interface model  
The air-liquid interface (ALI) organoid model has been previously established in the 
laboratory by Yasmin Nouri (MSc Candidate, Department of Biochemistry) and Tanis 
Godwin (ARF, Department of Biochemistry). Neonatal murine gastric tissue is embedded 
within a collagen matrix, and co-cultured with myofibroblasts in an inner well. This inner 
well sits within an outer growth medium-containing well, with medium reaching halfway up 
the collagen layer. This creates an air liquid interface [66].  
 
The ALI organoid model attempts to reproduce the in vivo environment as closely as 
possible. By using the whole neonatal mouse stomach both stem cells and differentiated cells 
are cultured, leading to all gastric cell lineages being present in the organoids [66]. The 
exposure to an air-liquid interface encourages differentiation into gastric surface mucous 
cells. These cells are normally exposed to the lumen within an in vivo stomach, and are not 
found in other liquid only organoid models [66]. Co-culture with myofibroblasts is 
representative of the stromal cells in vivo, which release growth factors to maintain the stem 
cell niche[67].  
 
 24 
1.4.2.2. Submerged model 
The submerged model is generated from adult mouse stem cells (aSC’s) which are obtained 
from the pit of the gastric glands of the pyloric end of the mouse stomach [65]. The term 
submerged is used as the mouse tissue is then placed within a matrix of Matrigel which is 
submerged in enriched growth medium [68].  
The benefits of the submerged 3D organoid model is the long term culture. Organoids fully 
develop within a week and are then able to be passaged and cultured again. This process is 
able to occur for over 8 months [65]. This process is medium throughput while still providing 
a 3D model of gastric cancer and all the different cell lineages. It is therefore a very useful 
tool for the testing of novel therapeutics.  
 
1.4.2.3. Additional models 
Other organoid models include the Induced Pluripotent stem cell (iPSC) model, where iPSCs 
are cultured into organoids on a Matrigel coated plate. The differentiation of iPSCs into the 
different cell lineages is directed through the addition of specific growth factors to the culture 
medium. This involves the daily addition of different growth factors and inhibitors to the 
organoid culture to induce the differentiation into different cell types from the pluripotent 
stem cells. This model is therefore very labour intensive. The iPSC model is a very low 
throughput model as the organoids are grown for 34 days, compared to 7 days for ALI and 
submerged[69].   
 
1.4.3 Mouse models  
Modelling gastric cancer in mice is an important final step prior to clinical trial for any 
potential therapy. Mouse models of gastric cancer show the tumour in its complete 
microenvironment, with all cell lineages present, and other organs and body systems to 
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represent fully the effect of treatment in vivo. While not being high throughput and easily 
manipulated, mouse models most accurately demonstrate the effects of novel treatments 
before the clinical trial phase[70].  
 
1.5. Aims  
The overall aim of this project was to validate synthetic lethal compounds which selectively 
inhibited CDH1-/ - cells, in three models of HDGC. Five compounds were studied, identified 
previously in our laboratory through a known drug screen. 2D and 3D models were used to 
identify the compound which displayed the most significant SL effect, to provide a base 
knowledge which can be applied to further trials for the development of a chemopreventative 
treatment option for HDGC patients. Ultimately, this compound has the potential to reduce 
both the risk of hereditary diffuse gastric cancer and the need for prophylactic gastrectomy. 
This aim was completed through three phases:  
- Preliminary analysis of the synthetic lethal effect of five compounds, HDACi’s and 
statins in a pair of NCI-N87 CDH1-/ - and CDH1+/+  isogenic gastric cancer cell lines, 
previously generated in the laboratory (Chen et al., 2019, manuscript in preparation). 
- Analysis of the previous clinical trial data of compounds which showed a significant 
SL effect in the NCI-N87 cell model was done. Compounds which were already FDA 
approved as cancer treatments, and showed significant selective inhibition of CDH1-/- 
in the NCI-N87 line, were then taken to the next phase of the project: validation in the 
ALI organoid model.  
- Thirdly a new organoid model, the submerged organoid model, was optimised to 
allow for a higher throughput 3D model for drug validation and to address limitations 
in the ALI organoid model. The submerged model was then used to further validate 
the SL effect of the compound with the most significant SL effect in the ALI model.  
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Chapter 2: Materials  
2.1 List of Reagents  
0.05% trypsin – prepared in the lab (dilution of 0.5% Trypsin at a 1:10 ratio with PBS)  
 
AlamarBlue – Thermo Fisher Scientifiic, USA  
Atorvastatin – Selleckchem, USA 
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich, USA 
Dulbecco’s modified Eagle’s medium and F12 (DMEM-F12) – Thermo Fisher Scientific, 
USA 
Endoxifen Hydrochloride Hydrate – Sigma-Aldrich, USA 
Entinostat – Selleckchem, USA 
Foetal bovine serum (FBS) – Invitrogen, USA 
Freezing medium – Prepared in lab  
Gentamicin (Gibco) – Thermo Fisher Scientific, USA  
GlutaMAXTM Supplement – Thermo Fisher Scientific, USA  
Hoechst 33342  - Thermo Fisher Scientific, USA 
Mocetinostat – Selleckchem, USA 
Nitta cellMatrix Collagen Gel Culturing Kit – Novachem, Australia 
Paraformaldehyde (PFA) – BDH Limited, England  
Phosphate buffered saline (PBS) solution – Prepared in lab  
(1 PBS tablet dissolved in 100 mL H2O, then autoclaved to sterilise.)  
Pracinostat – Selleckchem, USA 
Saponin – Sigma-Adrich, USA 
Vorinostat (SAHA) – Selleckchem, USA  
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2.2 List of Equipment  
      1 mL cryovials – Nunc, Denmark  
1.5 mL Eppendorf tubes – Sigma-Aldrich, USA 
10 mL serological pipettes – Greiner Bio-One, Germany  
10 cm Cellstar cell culture dish – Greiner, Germany  
15 mL Falcon tubes – BD Biosciences, USA  
24 well clear, flat bottom plates- Corning, USA 
30 mm Cellstar cell culture dish – Greiner, Germany  
50 mL Falcon tubes – BD Biosciences, USA 500 mL filter system - Corning, USA  
60 mm Cellstar cell culture dish – Greiner Bio-One, Germany  
75 mL cell culture flasks – Greiner Bio-One, Germany 
96 well black walled, clear, flat bottom plates – Corning, USA 
Centra 3C centrifuge – International Equipment Company, USA 
CO2 cell culture incubator – Binder, Germany 
ClarioSTAR microplate reader – BMG labtech, Germany  
Cytation 5 Imaging reader – BioTek, USA 
Dual chamber cell counting slides – Bio-Rad, USA 
Luna-IITM Automated cell counter – Logos Biosystems, South Korea 
Millicell cell culture inserts (0.4μm, 30mm) – Merck Millipore, Ireland 
Mr. Frosty 5100 Cryo 1°C Freezing Container – Thermo Fisher Scientific, USA  
Olympus CK2 Microscope – Olympus, New Zealand 
Tissue culture hood – EMAIL, Australia 




ImageJ – National Institute of Health, USA  
GraphPad Prism version 7.00 for Windows, GraphPad Software - La Jolla California USA  
Gen-5 software – Biotek, USA 
R version 3.6.0 - R Foundation for Statistical Computing, Vienna, Austria. [81] 
 
2.4 Ethics 
All animal procedures were completed according to University of Otago guidelines and 

















Chapter 3: Methods 
 
3.1. NCI-N87 culture 
NCI-N87 cells are a human gastric cancer epithelial cell line obtained from a high grade liver 
metastasis, therefore these cells have a high level of background mutations representative of 
in vivo cancerous tissue. An isogenic pair of NCI-N87 CDH1+/+ and CDH1-/- cell lines were 
generated previously by the Cancer Genetics laboratory through CRISPR-Cas9 methodology 
(Chen et al., 2019, manuscript in preparation).  
 
NCI-N87 cells are an adherent culture. Cells were grown in 75 mL angled neck cell culture 
flasks at 37°C and 5% CO2 in a humidified incubator. Complete culture medium contained 
80% Dulbecco’s modified Eagle’s medium and F12 (DMEM-F12) and 20% filtered (0.22 µm 
filter) foetal bovine serum (FBS). NCI-N87 cells were passaged once 80-90% confluence was 
reached. Prior to passage, 0.05% Trypsin-EDTA, PBS and complete growth medium were 
pre-warmed at 37°C in a water bath. Medium was aspirated from the flask and cells were 
washed with 5 mL PBS to remove any remaining growth medium. Then 3 mL of 0.05% 
trypsin-EDTA was added to the flask and left to incubate at 37°C for 5 minutes. 6 mL of 
complete growth medium was then added to each flask to neutralise trypsin activity and the 
cell suspension transferred to a 15 mL falcon tube. Cells were then centrifuged at 100 RCF 
for five minutes. Supernatant was aspirated and the pellet resuspended in 1 mL of complete 
growth medium. 
 
Cells were counted using a Luna-IITM Automated cell counter and re-seeded. 10 µL of 
resuspended cells was added to each end of a dual chamber counting slide. Two 
measurements of cell concentration were averaged, then used to calculate density of 
resuspended cells. NCI-N87 CDH1+/+ and CDH1-/- cells were plated at respective densities of 
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1x106 and 1.1x106  cells  per 75 mL cell culture flask. This seeding density allows both cell 
types to reach 80-90% confluency within seven days. Growth medium was changed every 3 
days during culture.  
 
3.1.1. Resurrection of NCI-N87 cells  
 
NCI-N87 cells were stored in liquid nitrogen vapour phase for long term storage. Cells were 
removed from liquid nitrogen and thawed in a 37 °C water bath. Cells were resuspended in 9 
mL of complete growth medium to dilute any remaining DMSO from the freezing medium, 
as DMSO is toxic to cells at temperatures above room temperature. Cells were then 
centrifuged at 100 RCF for 5 minutes. Supernatant was aspirated and the cell pellet 
resuspended in pre-warmed complete growth medium. Resuspended cells were then seeded 
into 75 mL cell culture flasks and incubated at 37°C and 5% CO2 in a humidified incubator. 
Growth medium was changed the following day to remove any non-adherent dead cells.  
 
3.1.2. Cryogenic preservation of NCI-N87 cells 
Following the passage protocol in methods section 3.1,  after trypsinisation, cell pellets were 
resuspended in freezing medium (80% complete media, 10% FBS and 10% DMSO) instead 
of complete growth medium, and aliquoted into 1 mL cryovials. Vials were then placed into a 
Mr Frosty Cryo 1C Freezing Container transferred to the -80°C freezer for 24 hours. This 
froze cells at a rate of 1C per minute. After 24 hours, vials were removed from the -80°C 
freezer and placed into liquid nitrogen for long term storage. 
 
3.1.3. NCI-N87 drug screening 
 
Drug aliquots were reconstituted in DMSO and stored at -20°C. Individual drug aliquots were 
further diluted in complete growth medium to create working stocks on the day of the assay.  
 31 
Cells were seeded in a 96-well plate (black walled, clear bottomed) at 10,000 cells per well in 
90 µL of complete growth medium. Plates were then incubated at 37°C and 5% CO2 in a 
humidified incubator. After 24 hours of incubation cells were treated with 10 µL drug or 10 
µL of 0.1% DMSO for negative control wells. The concentration of DMSO used was below 
the previously identified toxic concentration of 0.2%. A serial dilution of each drug was 
performed with concentrations ranging from 0.31 µM to 40 µM. Three technical replicates 







3.1.3.1. 24 hour edge count  
24 hours after seeding cells, a seeding accuracy check was completed. Cells in the outer wells 
were stained with Hoechst (1 µg/mL) in PBS and the plate was read in the cytation 5 imaging 
reader at 37°C and 5% CO2 . Six images were taken per well at  4x objective, with excitation 
and emission wavelengths of 377 and 447 respectively (Figure 4). The Gen5 software 
analysed fluorescence intensity and performed segmentation of nuclei to determine a total 
nuclei count per well.  
 
Figure 4: 96 well plate plan for NCI-N87 drug assay.                                                
Green = 10,000 NCI-N87 CDH1+/+ or WT cells per well. Grey= 10,000 NCI-N87 CDH1-/- or KO 
cells per well. Each cell type was treated with a serial dilution of drug, in triplicate for each 
concentration. Outer wells were used for a 24 hour edge count to validate seeding accuracy. 
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3.1.3.2. Cell viability assay  
After 48 hours of drug treatment, a total nuclei count was performed. Cells were fixed and 
stained with 0.075% saponin, 1 µg/mL Hoechst, and 0.25% paraformaldehyde solution 
(PFA) in PBS. Due to fixation, saponin was used as Hoechst is not able to penetrate the 
membrane of dead/fixed cells. 100 µL of this solution was added to each well of the 96-well 
plate on top of the media. Plates were left at room temperature in the dark for 30 minutes to 
allow the light sensitive solution to stain the nuclei. Plates were imaged in the cytation 5 
imaging reader at 6 fields per well. The Gen5 software calculated total nuclei counts from 
these images.  
 
3.1.3.3. Statistical analysis  
Prism software was used for the statistical analysis of NCI-N87 drug data. Drug 
concentration data was averaged and normalised to the respective CDH1+/+ and CDH -/-
DMSO controls, to account for any potential impact of the DMSO vehicle on cell viability. 
Grouped analyses with multiple un-paired student’s t-tests were performed for each drug, 
assuming non-consistent standard deviation. Statistical significance was determined as an 
adjusted p-value less than 0.05, correcting for multiple comparisons using the Holm-Sidak 
method.  
 
3.2. Air-liquid interface Organoid model  
3.2.1. Myofibroblast culture  
Myofibroblasts are a cell type found in mucosal surfaces like those of the gastrointestinal 
tract. When cultured they are an adherent cell type which look phenotypically similar to a 
fibroblast or smooth muscle cells [71]. The role of the myofibroblast in the mucosa is 
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structural and also involved in immune homeostasis, hence they are an important co-culture 
for the growth of gastric organoids [71].   
 
The Myofibroblasts cell line (MFB11) used in the ALI organoid protocol were previously 
isolated in the laboratory from a wildtype C57 Black 6 mouse (C57BL/6) using a protocol 
adapted from Pastula et al. [72]. MFB11 were used between passage 15 to no later than 
passage 22 for co-culture with organoids. MFB11 cells were cultured in a humidified 
incubator at 37C with 5% CO2 in 75 mL cell culture flasks. MFB11 complete culture media 
was made using Gibco DMEM/F-12 GlutaMAXTM supplement (80%) and 20% filtered FBS 
(0.22 µm filter).   
 
3.2.1.1 Passage  
The protocol for passage of the MFB11 cells is as per the passage protocol for the NCI-N87 
cells, as described in methods section 3.1. Minor changes to the protocol include incubation 
in 0.05% trypsin for 8 minutes and resuspension of cells in MFB11 media. Cells were then 
counted using the LUNA automated cell counter and re-seeded at 1x105 cells per 75 mL cell 
culture flask. At this seeding density MFB11 reached confluency in seven days. Complete 
culture media was changed every three days and cells passaged every seven days.  
 
3.2.1.2 MFB11 Resurrection 




3.2.1.3. Cryogenic preservation 
Cryopreservation of MFB11 cells is as per the cryopreservation protocol for NCI-N87 cells, 
described in methods section 3.1.3. 
 
3.2.2. Air-Liquid Interface Organoid Drug assay preparation 
The protocol used for the drug assay using the Air-liquid interface (ALI) organoid model has 
been developed and optimised in the laboratory by Yasmin Nouri and Tom Brew (PhD 
candidate, Department of Biochemistry).  
 
3.2.2.1. MFB co-culture preparation  
Six wells of ALI organoids were cultured for each drug assay, requiring a total of 6 x 106 
MFB11 cells for co-culture. Therefore, for every drug assay approximately thirteen confluent 
75 mL flasks of MFB11were required. MFB11 passage was completed initially as per 
protocol described above (Methods section 3.2.1.1.). After centrifugation, MFB11 were 
instead resuspended in 10xF12 Growth medium and cells pooled together in a 15 mL falcon 
tube.  
A dilution of 1:5 was done to allow for accurate cell counting, 10µL of this dilution was 
added to a dual chamber counting slide and cell count obtained. Two measurements of cell 
concentration were done, these were averaged to determine the density of resuspended cells. 
MFB11 were then placed on ice for organoid preparation.  
 
3.2.2.2 Organoid culture  
3.2.2.2.1. Collagen preparation: Base Layer 
A Collagen matrix was used for the growth of ALI gastric organoids. Work done with 
collagen was always on ice, as collagen sets at room temperature. For an ALI organoid 
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drugging protocol, six 30 mm dishes of organoids were required. 2.4 mL of collagen was 
used per well with an extra 30% to account for collagen wastage. Therefore, a total of 9.36 
mL collagen mix was prepared for the base layer, containing only MFB11. 
 
This included: 7.488 mL collagen, added to the tube on ice first so other components could 
be easily dispersed throughout the viscous solution.  A 0.936 mL solution containing 3.9x106  
MFB11 cells in F-12 Growth media. Lastly 0.936 mL of sodium bicarbonate, this was then 
gently mixed using a 10 mL stripette.  
 
Six 30 mm Milicell raised transwell inserts were placed inside 60 mm cell culture dishes. 1.2 
mL of the complete collagen solution was added to each of the six transwell inserts, lids were 
placed on the outer (60mm) dish and placed in the incubator at 37°C for 30 minutes for the 
collagen to set. The 15 mL falcon tube containing residual collagen with MFB11 in media 
and sodium bicarbonate was placed on ice and re-used for the preparation of the second layer, 
to avoid collagen wastage. 
 
Table 1: Concentration of components in CellMatrixTM collagen gel culturing kit for culture of the 





3.2.2.2.2 Mouse Euthanasia and stomach extraction  
Organoids were generated from 24-48 hour old mouse pup gastric stem cells. These mice 
were inducible knockout mice that have a cre-lox system controlling the knockout of CDH1-/- 
and the fluorescent marker Tdtomato under the CD44 promoter (CD44-cre/Cdh1-/-
Reagent Concentration (%) 
cellMatrixTM collagen solution Type I-A  80 
10x Ham’s F-12 growth medium  10 
Sodium bicarbonate buffer solution 10 
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/TdTomato). Mice were Euthanised by through decapitation by a sterile single-edge 10cm 
razor blade in a sterile 100mm dish. A sterile lid was placed over the dish and the mouse was 
then transferred to the tissue culture hood for stomach extraction.  
3.2.2.2.2.1 Stomach Extraction 
Once within the tissue culture hood, the mouse body was transferred from the dish in to the 
clean lid for stomach extraction. External specific scissors and forceps were used to complete 
the extraction. First forceps were used to manoeuvre the front and hind legs apart so that the 
stomach could be seen. Stomach was identifiable through the transparent skin of the mouse 
pup, as a large white organ under the skin on the right hand side. Sterile external specific 
scissors are used to cut directly above the stomach, which was then able to be pulled out 
through the incision by the forceps. Scissors were used to remove any additional 
gastrointestinal tissue that was attached to the stomach. The stomach was then placed in a 
30mm dish on ice containing 1mL of PBS with 50 µg/mL gentamicin for the first wash step.  
 
3.2.2.2.2.2 Stomach tissue wash 
External forceps and scissors were placed in ethanol to sterilise for the remaining stomach 
extractions. Sterile internal forceps and scissors were used for the four washes of the 
stomach. The stomach was gently cut open and all residual milk removed, this was done 
through gently pressing the forceps along the stomach so the milk residue is pushed out of the 
incision. Stomach tissue was transferred from each dish containing 1mL PBS and 50 µg/mL 
gentamicin to the next, four times, until the stomach was clean and all milk had been 
expelled. The whole stomach was then transferred to a 1.5 mL Eppendorf containing 100 µL 
PBS and 50 µg/mL gentamicin. Internal forceps and scissors were placed in ethanol to 
sterilise, while the second mouse was euthanised and brought into the tissue culture hood. 
This process was repeated four times for each ALI drug assay. All four stomachs were placed 
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into the same 1.5 mL Eppendorf with 100 µL PBS and gentamicin. For each new stomach 
extraction, sterile forceps and scissors were used, and 1mL PBS and gentamicin 50µg/mL 
was refreshed in each wash well.  
Once all four stomachs were in the 1.5 mL Eppendorf in 100 µL PBS and gentamicin, 
scissors were used to roughly mince the stomach tissue. Once the stomach tissue was as fine 
as possible, the smaller <0.5mm3, Westcott tenotomy scissors were used to even further 
mince the tissue ready for seeding.  
 
3.2.2.2.3 Collagen preparation: Tissue layer 
Once the stomach tissue was minced the second layer of collagen solution was prepared, 
using to the same ratio as for the first layer. A total of 9.36 mL was required for the 6 wells; 
7.448 mL collagen, 0.936 mL MFB in F12 growth media and 0.936 mL Sodium bicarbonate 
were combined in the 15 mL falcon tube used for the first collagen layer preparation (Table 
1). Minced stomach tissue within 100 µL of PBS and gentamicin, was spun at 800 g for 2 
minutes so that tissue collected at the base of the Eppendorf tube. The supernatant was 
aspirated, and tissue fragments were resuspended in 1 mL of the second layer collagen mix. 
This 1 mL of collagen containing stomach fragments was then transferred back to the 15 mL 
falcon tube containing the rest of the collagen mix, and gently and evenly mixed throughout.  
Inserts containing the now-set first layer of collagen, were removed from the incubator and 
placed inside the tissue culture hood. 1.2 mL of the 2nd layer collagen mix containing 
stomach tissue was added to each well. This was done carefully as to evenly distribute the 
stomach tissue around the well, so that organoids grew spread over the insert not all in the 
middle. Inserts containing a complete 2.4 mL of collagen were then placed back into the 
incubator at 37°C to set for 30 minutes.  
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3.2.2.2.4 Induction of CDH1 knockout 
Complete growth media for ALI organoids was made up of 80% F-12 GlutaMAXTM 
supplement media, with 20% FBS and 0.1% Gentamicin. To induce knockout (KO) of CDH1 
and activation of TdTomato, endoxifen was added at a concentration of 5 µM to the media on 
day 0. Endoxifen is a metabolite of tamoxifen, which induces cre-lox activation. For the day 
0 wild type CDH1 media, the equivalent amount of DMSO was added, as this was the vehicle 
for endoxifen. Identification of TdTomato fluorescence through microscopy in organoids 
treated with endoxifen, was used to confirm CDH1 knockout. It has been previously 
validated in our laboratory that organoids expressing TdTomato have approximately 73% 
homozygous knockout of CDH1 [73].   
Once collagen was set, 3 mL of complete growth media containing either endoxifen or 
DMSO, was added to each of the outer 60mm dishes (Figure 5). Three dishes of each 
condition, WT and KO were generated in preparation for the drug assay. Organoids were 
then placed in an incubator (37 °C, 5% CO2) for two days until drug treatment was added.  
 
Figure 5: Diagram of ALI organoid drug assay preparation.  
Organoids sit within a 2.4 mL collagen layer, in a 30mm insert. This sits within a larger 
60mm insert, containing 3 mL of complete growth medium. Top: Three CDH1 WT wells, 
treated with DMSO. Bottom: Three CDH1 KO wells, treated with Endoxifen.  
 39 
3.2.3. ALI drug screening 
After two days of culture at 37 °C and 5% CO2 in the incubator organoids were treated with 
drug. Media was removed from the outer well and replaced with 3 mL of media containing 
the drug at the required concentration. This treatment concentration was determined from the 
preliminary NCI-N87 cell culture drug screen data. Each treatment condition was added to 
two wells, one WT and one KO (Figure 6). A single WT/KO DMSO treated control was used 
for both drugs as the conditions of the experiment were the same. DMSO toxicity is seen in 
ALI organoids at concentrations higher than 0.05%, so for all experiments the final 
concentration of DMSO was 0.02%. Organoids were placed back into the incubator at 37 °C, 
5% CO2, and treated with drug for four days, until day 6 of the assay.  
 
Figure 6: Diagram of well conditions for ALI organoid drug assay.  
Three wells for both CDH1KO and CDH1 WT organoids, each WT and KO pair was to be treated 
with a different condition: DMSO, Drug 1 or Drug 2. 
 
 
3.2.3.1.Quantification of ALI organoid viability 
Organoids were imaged daily through brightfield microscopy on the Eclipse Ti Inverted 
microscope using the Fuji LAS-3000 ECL Imaging system, to track organoid growth. On day 
2 when drug treatment first started, and day 6, the final day of the assay, fluorescent images 
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were also taken. This was done on the Inverted microscope through the TRITC filter, to 
identify TdTomato fluorescence and successful CDH1 knockout. When imaging the 
organoids, the transwell insert remained within the outer 60mm dish.  
 
Brightfield images taken on day 2 (Day 0 of drug treatment) and day 6 (Day 4 of drug 
treatment) were used to quantify impact of the drug on organoid viability, through measuring 
change in organoid area. Using the measure tool on FIJI (ImageJ) the outline of each 
organoid was traced and an area measurement calculated. These two measurements allowed a 
growth change to be calculated for each individual organoid, and analysis of impact on 
growth from treatment to be completed. 
 
3.2.3.2. Statistical analysis  
Statistical analysis was undertaken in consultation with Associate Professor Mik Black 
(Department of Biochemistry, University of Otago). Area data of organoids on day 2 and day 
6 obtained from FIJI were logged (natural log), and the log-difference in area (day 6 minus 
day 2) was calculated for each sample. A single outlier observation (25-fold area increase 
over 4 days) was removed due to this being an implausible growth rate, most likely resulting 
from an error in the initial area estimate.  
 
Standard deviations were calculated per technical replicate, and these were used to determine 
the variability associated with each estimated log difference in area (average per technical 
replicate). For both KO and WT, each drug (Vorinostat and Mocetinostat) was standardised 
to DMSO by subtracting the mean (log scale). 
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A standardised estimate for the log difference in area was then calculated, and standard error 
calculated by combining error estimates from both technical and biological replicates, this is 
equivalent to using non-pooled standard deviation. Data were anti-logged to present as a 
percentage scale relative to DMSO. The mean difference in area estimates are presented as 
bar charts with associated standard error bars. These mathematical transformations were 
completed to take into consideration both technical and biological replicates and variability in 
the data. 
 
3.2.4 ALI-halo Organoid Analysis  
ALI organoids were seen to develop into two distinct phenotypes, true organoids and ‘halo’ 
organoids. The ALI drug assay was complete after 6 days, when the final area measurement 
was completed. However on day 6 the halo organoids appeared to disintegrate in the CDH1-/- 
wells treated with drug. To understand this interesting artefact and see if there was an SL 
effect occurring in these structures, halo organoids were imaged for a further 6 days, until day 
12 to see the impact of the drug over a longer term assay. Media was changed every three 
days however no further drug was added. A blinded assay on halo integrity was then carried 
out to investigate whether a SL effect could be seen in these structures. Halo organoid images 
from day 12 were blinded and then analysed for halo integrity. Analysis was done by at least 
two fully blinded individuals. If an image had a variation in integrity score it was further 
analysed by two other individuals. This assay was only completed once due to time 
constraints.  
 
3.3. Submerged Organoid model 
The protocol for the culture of submerged organoids was adapted from the established 
protocol developed in the Clevers laboratory ([65, 68].   
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3.3.1. Organoid preparation from primary tissue 
3.3.1.1. Stomach extraction 
For the preparation of inducible CDH1 knockout submerged organoids, CD44-cre/Cdh1-/-
/TdTomato mice were used, at between six to eight weeks old.  
 
Mice were euthanised through CO2 administration. Once breathing had ceased a cervical 
dislocation was done for confirmation of death. Stomach extraction was then completed. To 
do this, the mouse was placed onto a flat surface and pinned outstretched so that the abdomen 
was facing upward. Mouse abdomen was wet with 70% ethanol prior to the stomach removal 
procedure. A mucosal layer incision was done from the external genitalia to just below the rib 
cage. Skin was then pinned back to allow for a second incision into the mucosal layer, 
removing the abdominal musculature from the abdominal cavity. The stomach is situated on 
the right hand side, behind the liver and black in appearance. New sterile forceps and scissors 
were then used to remove the stomach from the abdominal cavity and remove any other 
gastro-intestinal tissue (oesophagus and duodenum). The whole stomach was then placed into 
a 50 mL falcon tube containing ice cold PBS.  
 
3.3.1.2. Gastric gland isolation and seeding 
Stomach was removed from 50 mL falcon and placed in a 10 cm dish. Stomach was opened 
along the greater curvature, which spans from the oesophagus to the duodenum. To remove 
mucus, the open stomach was washed twice in two 10 cm dishes each containing 35 mL of 
PBS. Once washed, dissection of the antral stomach was done, the antrum is pale in 
comparison to the body of the stomach.   
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The antral stomach was placed in a 50 mL falcon containing 25 mM EDTA, a chelating 
buffer and placed on a roller for 90 minutes at 4 ºC, this was done to loosen the adhesion 
between glands and the underlying stroma. Stomach was then removed from chelating buffer 
and placed into a 50 mL falcon tube containing 10 mL of ice cold PBS. This tube was shaken 
ten times to release the gastric glands from the stromal tissue into the PBS. Sterile forceps 
were used to remove any large pieces of tissue from the solution. This was then spun for 5 
minutes at 200 g at 4 degrees. Supernatant containing PBS was removed and the glands were 
resuspended in 10 mL of ice cold basal medium.  
To isolate the glands from the solution, the suspension was passed through a 70µM cell 
strainer into a 15 mL falcon tube on ice. Extra basal media was washed through the strainer 
to obtain all the gastric glands, large pieces of muscle tissue not required for the organoid 
prep cannot pass through the strainer. The basal medium containing gastric glands was then 
spun at 200 g for five minutes at 4 degrees, then supernatant was removed leaving only gland 
tissue in the tube. Maximum amount of supernatant was removed as Matrigel proteins can be 
diluted inhibiting organoid growth. The glands were resuspended in the quantity of Matrigel 
required for seeding (50 µL per well) plus 10% extra to account for the dead volume of 
Matrigel. 50 µL of this Matrigel/gastric gland suspension was placed into each well required 
of a pre-warmed 24 well plate.  Plate was then placed in the incubator at 37°C for 10 minutes 
to allow Matrigel to set.  500 µL of complete submerged growth medium was added to each 
well (Table 2) and the plate placed back into the incubator at 37C and 5% CO2. The initial 
organoid preparation from the mouse gastric tissue was done in our lab by Tom Brew.  
 
3.3.2. Media components  
Complete growth medium was prepared fresh for each medium change according to the 
concentrations in Table 2. Once all components of the medium were combined, media was 
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placed in the water bath to warm to 37°C prior to addition to organoids. Basal medium was 
prepared according to Table 3, as needed and stored at 4°C. When required for use, basal 
media was placed on ice.  
 
Table 2: Complete growth medium for submerged organoids 
Reagent Final concentration 
Advanced DMEM/F12 N/A 
HEPES 10 mM 
GlutaMAX 2 mM 
Pen/Strep 1x 
N-acetylcysteine 1 mM 
Gastrin 10 nM 
EGF 50 ng/mL 
R-Spondin1-conditioned medium 10% 
Noggin-conditioned medium 10% 
FGF10 100 ng/mL 
Wnt3a-conditioned medium 50% 
Y-27632 (RHOK inhibitor) 10 µM 
B27 1x 
N2 1x 
A 83-01 2 µM 
 
Table 3: Basal medium for submerged organoid passage 
Reagent Final concentration 
Advanced DMEM/F12 N/A 
HEPES 10 mM 
GlutaMAX 2 mM 
Pen/Strep 1x 
 
3.3.3. Submerged organoid culture  
Submerged organoids were grown at 37C, 5% CO2 in an incubator, within a 24 well plate in 
500 µL media. Media was made as per table 2, and was changed every 3 days.  
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3.3.3.1. Submerged organoid passage  
After 7 days of growth, submerged organoids were passaged. 500 µL media was aspirated 
from each well so that 50 µL Matrigel dome was exposed. 1 mL cold basal medium (Table 3) 
was added to the well and vigorously pipetted up and down to disrupt the Matrigel. A 1mL 
pipette tip was also used to physically scrape Matrigel in the well. This organoid and 
Matrigel suspension in basal media was then transferred to a 15 mL falcon tube. Up to three 
wells were pooled together in this process, as increased quantities of Matrigel lead to 
difficulties in organoid isolation. Cold basal media was added to the falcon tube until the 
solution reached 15 mL. This organoid suspension was then centrifuged at 4C for 5 minutes 
at 200 g. Supernatant (basal media and Matrigel) was removed, leaving 2 mL at the base of 
the falcon tube. The organoid pellet was then resuspended in this 2 mL solution. Organoids 
were then further mechanically disrupted with a 20 G needle attached to a syringe, by 
aspirating and dispensing the entire solution six times. Cold basal media was added so the 
solution was again 15 mL. The solution was then centrifuged at 100 RCF for 5 minutes at 
4C. All supernatant was aspirated from the organoid fragment pellet. Fragments were 
resuspended in 150 µL Matrigel using precooled pipette tips and counted on a 
haemocytometer.  
 
Organoid fragments were re-seeded at 500 fragments in 50 µL of Matrigel per well. Matrigel 
containing organoid fragments was gently pipetted using pre-cooled pipette tips, to the centre 
of each well in the pre-warmed 24 well plate. Pipette tips were pre-cooled to stop Matrigel 
polymerisation and wastage during seeding, and the 24 well plate pre-warmed so Matrigel 
polymerised quickly once in the well, creating a defined Matrigel dome. Plate was placed 
back into incubator for 10 minutes to allow Matrigel to fully polymerise. 500 µL of complete 
submerged organoid growth media (Table 2) was then added to each well. PBS was added to 
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remaining empty wells to reduce evaporation effect. Media was changed every three days and 
organoids cultured for 7 days until the next passage was required. 
 
3.3.4. Submerged organoid drug screening 
For the drug screening protocol, submerged organoids were grown from single cells rather 
than fragments, to allow for uniform organoid growth. Methods section 3.4.3.1. Submerged 
organoid passage was adapted for organoid single cell preparation. Following on from the six 
aspirate – dispense cycles with the 20 G needle, the organoid suspension was further 
fragmented using a 1 mL pipette. Organoid suspensions were then pooled if more than 3 
wells were passaged. Basal medium was added to the organoid fragment suspension to a 
volume of 15 mL. The suspension was then centrifuged at 200 RCF at 4C for five minutes.  
 
Supernatant was aspirated and organoid fragments resuspended in 1 mL of 0.05% Trypsin-
EDTA, which was pre-warmed to 37C. Fragment suspension in trypsin was then placed into 
the incubator and left for 10 minutes to generate single cells. Every two minutes 10 µL of the 
suspension was placed in a cell counting slide and percentage of single cells was checked to 
ensure over digestion did not occur. After 10 minutes 10 mL of medium containing 20% FBS 
was added to the suspension to quench trypsin activity. The suspension was then centrifuged 
for 5 minutes at 500 RCF at 4C to pellet. Supernatant was discarded and organoid single 
cells were resuspended in Matrigel and counted on the LUNA automatic cell counter.  
 
1000 organoid single cells were added in 50 µL of Matrigel to each well of a pre-warmed 96 
well black walled, clear flat bottom plate. Three wells were seeded with Matrigel containing 
no organoid cells as a blank for the viability assay to read background fluorescence. Matrigel 
was added with pre-cooled pipette tips, slowly pipetting upward in the centre of the well. 
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This was done to avoid the spread of organoids to the edge of the well. Plated organoids were 
then placed back in the incubator at 37 C for 10 minutes for the Matrigel to polymerise. 100 
µL of complete growth media was then added to each well.  
 
3.3.4.1. CDH1 knockout Induction  
To induce knockout of CDH1 and activation of TdTomato, endoxifen is added at a final 
concentration of 5µM to the media after 24 hours. Endoxifen is a metabolite of tamoxifen, 
which induces cre-lox activation. The Endoxifen is added in 100 µL of complete growth 
medium, which is added on top of the original 100 µL of medium in the well, so organoids 
are not disrupted. For the day 1 wild type CDH1+/+ media, the equivalent amount of DMSO is 
added, as this is the vehicle for endoxifen.  
 
3.3.4.2. Drug addition  
On day two, a serial dilution of drug was produced with each dilution being double the 
concentration required in the assay. 100 µL was aspirated from each well in the plate, and 
100 µL of drug in complete growth medium was added. As 100 µL of complete growth 
media was still present in the well, the drug concentration was doubled. Plate was placed 
back into the incubator and cultured until viability was assayed after 48 hours. 
 
3.3.4.3. Viability assay  
The AlamarBlue metabolic assay was utilised to analyse submerged organoid metabolic 
activity, which was used to infer organoid viability. This is a fluorescent assay where 
metabolically active cells are able to convert a non-fluorescent blue reagent Resazurin to a 
fluorescent product resorufin. While non-viable cells are not able to convert Resazurin to the 
fluorescent product. Submerged organoids were incubated in complete growth medium 
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supplemented with 10% AlamarBlue, for 18 hours at 37 ºC and 5% CO2. This analysis was 
done after 48 hours of drug treatment. Total fluorescence was analysed on the CLARIOstar 
microplate reader.  
 
3.3.5. Cryogenic preservation  
Freezing media was prepared as per Table 4, and pre-cooled. Protocol for passage of 
submerged organoids was followed, however instead of re-suspension in Matrigel, fragments 
were resuspended in Advanced DMEM/F12 and counted. Submerged organoids were frozen 
at 1000 fragments per cryo-vial. The quantity of submerged organoids was added to each 
vial, and then topped up to 1 mL total solution with Freezing media, as per Table 4. Cryo-
vials were placed into a Mr Frosty and quickly placed into the -80C freezer overnight. 
DMSO is toxic to cells at room temperature, hence why freezing media is pre-cooled and 
why the Mr frosty is swiftly placed at -80C. Cryovials are then transferred to liquid nitrogen 
for long term storage.  
 
Table 4: Submerged organoid freezing medium 
Reagent  Concentration  
Advanced DMEM/F12 80% 
Fetal Bovine Serum (FBS) 10% 
DMSO 10% 
3.3.6.   Resurrection of submerged organoids  
Cryo-vials of frozen submerged organoid fragments were removed from LN2 and defrosted in 
a 37 °C water bath. After defrosting, fragments were immediately transferred to 15 mL 
Falcon tubes containing 5 mL of basal media (Table 3) and centrifuged at 200 g  at 4C  for 5 
minutes to pellet. Supernatant was then removed and fragments were resuspended in 
Matrigel. Matrigel containing organoid fragments was then seeded in 24 well plates – one 
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vial into one well- and left to polymerise for 10 minutes. Then 500 µL of complete culture 





















Chapter 4: Results  
4.1 NCI-N87 drug assay data  
The initial phase of this project involved validating the SL effect of compounds identified in 
the known drug screen (see section 1.3.1.) through testing in the gastric cancer NCI-N87 
CDH1+/+ and CDH1-/- isogenic cell lines. This 2D model allows for high throughput screening 
of potential SL candidates at multiple concentrations and validation of effectiveness in a 
gastric cancer cell line. The NCI-N87 drug assay was carried out according to the protocol 
described in methods section 3.2. Drug effect was analysed through a measurement of nuclei 
count, which was used to infer cell viability.  
 
4.1.1. Atorvastatin 
To test the SL effect of Atorvastatin, NCI-N87 cells were treated with a concentration range 
from 0.31 µM to 40 µM according to the protocol described in the methods section 3.2. None 
of the tested concentrations show a significant SL effect, with CDH1-/- cells maintaining a 
similar nuclei count compared to CDH1+/+ cells, particularly at lower drug concentrations 
(Figure 7). At concentrations above 5 µM, although not statistically significant, there is a 
suggestive SL trend with lower CDH1-/-  cell nuclei count compared to CDH1+/+ (Figure 7). 
The closest concentration to a significant SL effect is the 20 µM concentration with an 
adjusted p-value of 0.069.  
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Figure 7: Normalised nuclei counts 48 hours post treatment with a serial dilution of 
Atorvastatin.  
An isogenic pair of NCI-N87 cells used: CDH1+/+ (green bars) and CDH1-/-(grey bars). Cells 
were treated with a serial dilution of Atorvastatin, ranging from 0.31 µM - 40 µM. No 
significant difference between NCI-N87 CDH1+/+ and NCI-N87 CDH1-/-  cell viability was 
observed. Data represents averaged values of four biological replicates with standard error 
shown. Holm-Sidak adjusted p-values were calculated using student’s t-test.   
 
4.1.2 Histone Deacetylase inhibitors 
The four histone deacetylase inhibitor (HDACi) compounds identified as SL in the 
preliminary known drug screen [47] were validated in the NCI-N87 CDH1-/- and CDH1+/+  
model. Cells were treated with a range of concentrations of four HDACi: Entinostat, 
Pracinostat, Mocetinostat and Vorinostat. Cells were treated for 48 hours and viability 
analysed through a Hoechst stain nuclei count on the Cytation plate reader according to the 
protocol in methods section 3.2. All four HDACi tested showed a significant SL effect at one 
or more concentrations. 
 
4.1.2.1 Entinostat 
Entinostat specifically inhibits class I HDACs, which are known to be overexpressed in some 
gastric cancers [56]. Entinostat showed a significant SL effect at concentrations of 1.25 µM, 



























2.5 µM and 40 µM. Adjusted p-values were 0.029, 0.011 and 0.049, respectively. All other 
concentrations show an SL trend, with CDH1+/+  cells maintaining higher viability than their 
knockout counterparts, however are not significant (Figure 8). Overall, the NCI-N87 CDH1-/-
/CDH1+/+ cell culture analysis has validated Entinostat as a potential SL compound, and is 
consistent with previous drug screening in MCF10A cells [47]. 
 
Figure 8: Normalised nuclei counts 48 hours post treatment with a serial dilution of 
Entinostat.  
An isogenic pair of NCI-N87 cells used: CDH1+/+ (green bars) and CDH1-/-(grey bars). Cells 
were treated with a serial dilution of Entinostat, ranging from 0.31 µM - 40 µM. A 
significant synthetic lethal response was seen in NCI-N87 CDH1-/- cells at 1.25M, 2.5M 
and 40M. µM = micro molar. Data represents averaged values of three biological 
replicates with standard error shown. Holm-Sidak adjusted p-values calculated using 
student’s t-test *P<0.05; **P<0.01,***P<0.001.  
4.1.2.2. Pracinostat 
NCI-N87 cells were treated for 48 hours with a serial dilution of Pracinostat, with 
concentrations ranging from 0.31 µM to 40 µM, according to the protocol described in 
methods section 3.2. Pracinostat showed a significant SL effect at concentrations of 0.31, 
0.63, 1.25 and 20 µM, p-values of 0.006, 0.003 and 0.014, and 0.038 respectively (Figure 9). 
All other Pracinostat concentrations showed an SL trend, with CDH1+/+  cells maintaining 
higher viability than the CDH1-/-, however these were not statistically significant. Treatment 




























with ≥1.25 µM Pracinostat strongly decreased the viability of both cell lines (Figure 9). 
Although some concentrations within this range show significant SL, a 50% decrease in 
viability of CDH1+/+ cells, representing healthy gastric cells, would clearly be harmful to the 
patient. 
 
Figure 9: Normalised nuclei counts 48 hours post treatment with a serial dilution of 
Pracinostat.                                              
An isogenic pair of NCI-N87 cells used: CDH1+/+ (green bars) and CDH1-/-(grey bars). Cells 
were treated with a serial dilution of Pracinostat, ranging from 0.31µM - 40 µM. A 
significant synthetic lethal response was seen in NCI-N87 CDH1-/- cells at concentrations 
including and below 1.25M, and at 20M. µM = micro molar. Data represents averaged 
values of three biological replicates with standard error shown. Holm-Sidak adjusted p-
values calculated using student’s t-test *P<0.05; **P<0.01,***P<0.001. 
 
4.1.2.3. Mocetinostat 
Mocetinostat demonstrated the most significant SL effect compared to all other compounds 
assessed in this project, with every concentration showing a significantly decreased viability 
(p-value <0.05) in CDH1-/- cells relative to CDH1+/+ (Figure 10). Results were done in 
triplicate according to the aforementioned protocol. Highly significant results were seen at 
the 10µM an 40 µM concentrations, both having an adjusted p-value of 0.0089. The 
significant synthetic lethal effect seen at concentrations of ≤ 1.25 µM (adjusted p-values 






























0.006, 0.003, 0.014) is particularly encouraging since the CDH1+/+ cell viability is unaffected, 
while the CDH1-/- cell viability has decreased by 20-30%.  At concentrations above 1.25 µM, 
the viability of both cell lines decreases (Figure 10). In a clinical context, potential 
chemopreventative compounds will need to have a minimal impact on CDH1+/+ cells, to 
minimise side effects on the patient. Lower concentrations of Mocetinostat are therefore 
preferable as the CDH1+/+ cell viability is unaffected. 
 
 
Figure 10: Normalised nuclei counts 48 hours post treatment with a serial dilution of 
Mocetinostat.                                             
 An isogenic pair of NCI-N87 cells used: CDH1+/+ (green bars) and CDH1-/-(grey bars). Cells 
treated with a serial dilution of Mocetinostat, ranging from 0.31 µM - 40 µM. A synthetic 
lethal response was seen in NCI-N87 CDH1-/- cells at all concentrations. Data represents 
averaged values of three biological replicates with standard error shown. Holm-Sidak 
adjusted p-values calculated using student’s t-test *P<0.05; **P<0.01,***P<0.001. 
 
4.1.2.4. Vorinostat  
Vorinostat is the final drug tested in the NCI-N87 model, cells were treated for 48 hours with 
a serial dilution of Vorinostat, with concentrations ranging from 0.31 µM to 40 µM. 
Vorinostat showed a significant SL effect at a concentration of 1.25 µM with an adjusted p-
value of 0.035 (Figure 11). The 2.5 µM and 5 µM concentrations also display an inhibition of 


































CDH1-/-  cells compared to the WT, however not significant. All other concentrations 
maintained a minor SL trend, with CDH1+/+  cells having a slight higher viability than their 
knockout counterparts (Figure 11).  
 
Figure 11: Normalised nuclei counts 48 hours post treatment with a serial dilution of 
Vorinostat.                                           
 An isogenic pair of NCI-N87 cells used: CDH1+/+ (green bars) and CDH1-/-(grey bars). Cells 
were treated with a serial dilution of Vorinostat; 0.31µM - 40 µM.  A modest synthetic lethal 
response was seen at 1.25M In NCI-N87 CDH1-/- cells. Data represents averaged values of 
three biological replicates with standard error shown. Holm-Sidak adjusted p-values 
calculated using student’s t-test *P<0.05; **P<0.01,***P<0.001. 
 
4.2. ALI Organoid data   
The ALI gastric organoid model is a medium throughput 3D model of gastric cancer. ALI 
organoids develop from neonate mouse gastric stem cells, leading to differentiation into 
spherical structures made up of all gastric cell lineages. Organoids are grown in a collagen 
matrix containing a co-culture of myofibroblasts, at an air-liquid interface [66]. Although 
organoids are a lower throughput model compared to the NCI-N87 cell model,  organoids are 
a more representative of the in vivo gastric environment, therefore more beneficial and 
informative screening tool.  The ALI organoid culture model and drug assay was optimised 
previously based off the Ootani et al. protocol, in the cancer genetics lab by Yasmin Nouri 




























and Tanis Godwin [66]. In this section, two drugs screened in the NCI-N87 cell line, 
Mocetinostat and Vorinostat were further validated in the ALI organoids. 
 
4.2.1. ALI drug screening 
ALI organoids were generated from murine gastric tissue and cultured for two days prior to 
drug addition. To develop the CDH1-/- organoids, knockout of CDH1 was induced by 
endoxifen on day zero. Organoids were then treated with drug for four days. Organoid area 
was measured on day 2 (day of drug addition) and day 6 (final day of assay) (Figure 12) 
using FIJI and the growth rate calculated. This was used as a comparative measure of 
viability. The concentrations of Vorinostat and Mocetinostat used in the ALI model were 
based off the NCI-N87 data (results sections 4.1.2.3 and 4.1.2.4).  
 
The percentage change in growth measurement was used to analyse viability of the ALI 
organoids and to identify any SL effect (Figure 13). To find this, area was measured for each 
organoid on day 2, before drug addition, and on day 6, after 4 days exposed to drug. Area 
measurements were done manually using FIJI. Area data was then logged and subtracted to 
find the log change in growth. Log form of area data was used so that analysis was done in 
additive scale and error bars could be calculated. A log scale also accounts for variation in 
organoid sizes and number. Growth rates for each drug treatment group were normalised to 
the corresponding DMSO control (CDH1+/+ or CDH1-/- control). 
 
DMSO percentage change in growth is displayed as 100 (dotted line) on the graph (Figure 
13). Data is not statistically significant, as the confidence intervals for the CDH1+/+ and 
CDH1-/- for each treatment showed complete overlap, therefore no statistical test was done. 
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Data were anti-logged to present as a percentage scale relative to DMSO. Statistical analysis 
of was undertaken in consultation with Associate Professor Mik Black. 
 
4.2.1.1. Vorinostat 
Vorinostat was chosen to be taken through into the ALI model as it showed a significant SL 
effect in 2D cell culture, and is also already FDA approved for the treatment of 
haematological cancers [62]. Therefore it is a promising compound if an SL effect is present, 
as prior understanding of safety and toxicity will allow for approval of future clinical trial and 
treatment production for HDGC. ALI organoids were treated for four days with 5 µM of 
Vorinostat as per the protocol described in the methods section 3.2. This 5 µM concentration 
was chosen as previous data from Vorinostat treatment of ALI organoids showed that no 
response was seen at lower concentrations [74]. Three biological replicates were completed, 
representative images of organoids treated with Vorinostat and DMSO control are shown in 
Figure 12. 
 
Control organoids were treated with DMSO. Uninduced CDH1+/+ DMSO treated organoids 
(Figure 12A) showed a normal growth rate from day 2 to day 6, and a healthy morphology 
consisting of a transparent spherical structure with an intact outer wall of gastric cells. 
Induced CDH1-/- organoids treated with DMSO presented with the same phenotype, clear 
lumen and no signs of necrotic cells, indicating no effect on organoid viability from 
endoxifen treatment. 
 
After four days of 5 µM Vorinostat treatment, both uninduced (CDH1+/+) and induced 
(CDH1-/-) organoids had a similar phenotype to the DMSO treatment group, as intact spheres 
of transparent tissue (Figure 12A & B). More images of Vorinostat treated organoids can be 
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seen in Appendix 1. The data shows that 5 µM of Vorinostat has not had a visible effect on 
organoid viability. This suggest that a higher concentration of Vorinostat will need to be 
tested to translate the SL effect seen in cell culture into the ALI model. 
 
Vorinostat treatment in the ALI organoids also showed no SL effect in percentage change in 
growth (Figure 13). Change in growth between CDH1+/+ and CDH1-/- organoids were similar 
and there was a slight increase in growth compared to DMSO (100) (Figure 13). There was 
considerable variation in both size and number of Vorinostat treated organoids, with a range 
of 3-17 organoids per well with different sizes. Although change in growth is an accurate 
measure, it is insufficient to account for all the variation. 5µM Vorinostat did not have any 
effect on growth rate in the CDH1-/- organoids. The concentration of Vorinostat will be 
increased in further experiments to try and replicate the SL effect seen in the NCI-N87 
model. 
 
4.2.1.2. Mocetinostat  
Mocetinostat was further validated as an SL compound in the ALI model due to its 
significant SL effect at every concentration in the NCI-N87 model. Mocetinostat was 
originally tested at a concentration of 2.5 µM, however this concentration was lethal to both 
CDH1+/+ and CDH1-/- organoids, so the concentration was lowered to 0.63 µM for further 
experiments. Mocetinostat at 0.63 µM was added to organoids at day 2 and cultured until day 
6 when the viability of organoids was tested. Representative images of induced CDH1-/- and 
not induced CDH1+/+ organoids treated with Mocetinostat are shown in Figure 12. DMSO 
controls are representative for both drugs, as each experiment trialled two drugs, at the same 
DMSO concentration, with the same gastric tissue.   
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Uninduced CDH1+/+ organoids treated with 0.63 µM Mocetinostat had a normal growth rate 
and displayed no signs of death, maintaining the intact transparent phenotype (Figure 12A). 
However the CDH1-/- organoids displayed clear signs of death. Following drug treatment the 
organoid on day 6 has dark granular cells within then lumen indicating the presence of 
necrotic cells. There was also disintegration of the organoid wall (see for example the lower 
left side of the D6 treated organoid in Figure 12B. Visually the phenotypes display an SL 
trend, CDH1+/+ organoids maintain a healthy phenotype similar to the DMSO control, while 
CDH1-/- organoids show signs of death. ). These images indicate CDH1-/- ALI organoids 
treated with Mocetinostat may be more sensitive than wild type CDH1+/+. Further images of 
organoid disintegration due to Mocetinostat treatment are in Appendix 2. To quantify the 
observed effect, a qualitative measurement and analysis on percentage change in growth was 
done.  
 
Mocetinostat treatment, however, did indicate a difference in growth rate between the 
CDH1+/+ and CDH1-/- organoids, although it was not significant (Figure 13). The data is 
suggestive of increased sensitivity of CDH1-/- organoids to treatment of 0.63 µM of 
Mocetinostat, compared to WT. However it will need to be further analysed through more 
replicates within the ALI model, or testing in an alternative model that is less prone to 




Figure 12: Representative brightfield images of Air-Liquid interface (ALI) organoids 
treated with DMSO (control), Vorinostat and Mocetinostat.  
(A) Uninduced (Wild type) organoids on day 2 (D2) and day 6 (D6), treated with 0.1% 
DMSO, 5µM Vorinostat and 0.63µM Mocetinostat, exhibiting healthy growth patterns and 
appearance. (B) Induced (CDH1 Knockout) organoids on D2 and D6, treated with 0.1% 
DMSO, 5µM Vorinostat and 0.63µM Mocetinostat. DMSO and Vorinostat treated organoid 
are exhibiting healthy growth and appearance, Mocetinostat treated organoid showing a 





Figure 13: Percentage change in growth analysis of ALI organoids treated with Vorinostat 
and Mocetinostat. 
Area data of day 2 and day 6 was logged and subtracted to obtain the change in growth. 
Data was unlogged back to a percentage scale and normalised to DMSO, indicated by the 
dotted line at 100% growth rate. Error bars are standard error. Green bar = CDH1+/+ 
organoids and grey bar =  CDH1-/- organoids. Graph produced in consultation with 
Associate Professor Mik Black.  
 
 
4.2.2. ‘Halo’ organoids 
4.2.2.1 Identification of Halo organoids  
Two types of organoid growth develop in the ALI model. Firstly ‘true’ organoids (Figure 
14A) occur where a substantial population of gastric stem cells are present in the primary 
tissue piece, which are able to proliferate rapidly into a spherical monolayer of epithelial cells 
with a clear lumen, similar to in vivo gastric glands. The myofibroblast co-culture supports 
CDH1 +/+ Organoids 
CDH1-/-  Organoids 
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this growth through the release of growth factors and the collagen matrix for support of the 
3D structure. True organoids were analysed for percentage change in growth and considered 
a true representative model of the in vivo gastric gland.  
The other form of growth that can occur in the ALI model has been termed a ‘halo’ organoid, 
which occurs when the primary tissue remains within the proliferative cells and a ring of 
organoid tissue surrounds the primary tissue. The true cystic organoid structure does not form 
as the primary tissue remains to support the proliferative cells (Figure 14B). These are termed 
‘halo’ organoids as the proliferative growth around the primary tissue looks like a floating 
halo. These structures grow when there likely aren’t enough stem cells in the tissue, the tissue 
is too large to be degraded or growth factors secreted by the myofibroblasts were not 
sufficient. Approximately 15-20 of these structured were present per well. Imaging of these 
‘halo’ structures was performed to better understand organoid development and to see if the 
impact of the drugs on these structures was different to the true organoids.  
 
 
Figure 14:Comparative image of a true organoid compared to a ‘halo’ organoid.  
(A)True organoid, clear cystic structure, clear lumen with no residual primary tissue. (B)’Halo’ 
organoid, primary tissue clearly visible as black centre with proliferative growth surrounding. 
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The ALI drug assay was completed after day 6, when the final area measurement was taken. 
However, it was noticed  that the halo organoids started to disintegrate on day 6 in the CDH1-
/- wells treated with drug. To understand this interesting artefact and see if there was a 
differential effect occurring in these structures (CDH1-/- vs. WT), halo organoids were further 
imaged until day 12 to determine the impact of the drug over a longer term. Media was 
changed every three days but no further drug was added. Figure 15 shows the comparison of 
CDH1+/+ and CDH1-/-  halo organoids treated with Vorinostat on day 6 and then day 12. The 
halo for the CDH1+/+ organoid has remained intact (Figure 15A) while the CDH1-/- organoid 
treated with Vorinostat has disintegrated, there is no halo left surrounding the primary tissue 
(Figure 15B). To quantify this observation, a blinded assay on halo integrity was then carried 
out to investigate whether a differential effect could be seen in these structures following 
treatment with both Vorinostat and Mocetinostat.  
 
Figure 15: Representative images of halo degradation in 5µM Vorinostat treated ALI organoids.  
(A) CDH1+/+ halo organoid on day 6 and day 12 treated with 5 µM Vorinostat. Halo surrounding 
primary tissue has remained intact over the 6 days of growth. (B) CDH1-/- halo organoid on day 6 and 




4.2.2.2. Halo organoid analysis  
85 halo organoid images from day 12 were blinded and then analysed for halo integrity. 
Analysis of each image was done by at least two individuals (not the author). Images were 
removed of all labels and renamed alphabetically and randomised, then individuals were 
asked to score halo integrity or disintegration. If an image had a difference in integrity score 
it was further analysed by two other individuals. Figure 16 shows the data from the blinded 
analysis. A minimum of 10 halo organoids are in each treatment group. DMSO treated halos 
present a similar percentage of disintegrated organoids in both CDH1+/+ and CDH1-/- groups. 
With around 80-90% of the halos remaining intact. Vorinostat CDH1+/+  halos are similar to 
DMSO with around 80% remaining intact, CDH1-/- Vorinostat treated had just over 60% of 
halos remain intact, which is a slight SL trend. However, Mocetinostat halo organoids 
demonstrated a strong SL effect with 100% of the CDH1-/- organoids being classified as 
disintegrated, while over 60% in the CDH1+/+ group remained intact (Figure 16). This assay 
was only completed once due to time constraints. Results from this assay were similar to that 
of the true organoid growth rate analysis. This is an interesting result that will need to be 
further replicated and the halo organoids characterised to understand the artefact occurring.  
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Figure 16: ALI halo organoid integrity blinded analysis.  
Green bars indicate Intact halos and grey indicates a disrupted halo. WT are organoids have 
functional CDHI. KO are organoids which have been induced with endoxifen and CDH1 has 
been knocked out.  
 
In summary, the ALI model has provided a valuable 3D model to investigate further the in 
vivo SL capabilities of Vorinostat and Mocetinostat.  The analysis in the ALI model has 
shown that the SL trend of Mocetinostat seen in NCI-N87 culture, is also a trend in the ALI 
organoids, both within the true organoids and the halo organoids. Variation within the ALI 
model has meant data has been difficult to process, and significance hard to define. Overall 
SL trends are able to be observed, but the variability of the ALI model has precluded firm 
conclusions. For this reason we investigated a second organoid model – the submerged 
model. 
4.3. Submerged organoid data:  
The third phase of this project is the optimisation of a new organoid model,  submerged 
organoids, in order to develop a higher throughput, more consistent organoid model for SL 
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drug screening. The submerged model was originally established in the Clevers laboratory, 
and involves organoids being grown within a Matrigel matrix and fully submerged in growth 
factor-enriched media [65, 68]. Some of the limitations discovered with the ALI model are 
able to be overcome with the submerged organoids. Fresh gastric tissue is not required for 
each experiment, as they are able to be passaged. This is less time consuming and means the 
model is higher throughput. Secondly, the variation in size and organoid number seen with 
the ALI model organoids can be avoided as the submerged organoids are seeded as individual 
cells, which can be counted and all grow into similar size organoids.  
 
Prior to the start of this project, many of the culture conditions and protocol for the 
submerged organoid model had been established by Tom Brew based on the protocols from 
the Clevers laboratory[65, 68]. As per ALI organoids, there is the same inducible CDH1-/- 
knockout model for the submerged organoids. This phase of the project involved optimisation 
of specific conditions for the submerged model, investigation into the addition of a TGFß 
inhibitor, seeding density analysis for the drug protocol and lastly looking into the DMSO 
toxicity of these organoids. Followed by, a pilot Mocetinostat drug assay completed. More 
replicates of the drug assay could not be done in the time frame of this project.  
 
4.3.1. TGFßi addition to growth media  
During propagation culture of the submerged organoids, certain organoids would develop an 
adhered phenotype with budding growths, rather than the spherical organoids which are 
representative of the gastric gland. This was hypothesised to be a form of epithelial to 
mesenchymal transition (EMT). TGFß is known to be related to the cause of EMT due to its 
upregulation of WNT signalling which activates EMT [75]. TGFß is a component of the 
Matrigel used for the submerged organoid culture, however concentration of the protein 
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varies per batch. A higher TGFß concentration could lead to more EMT organoids and a 
redundant drug assay. Although not always present in submerged organoid media [65], the 
addition of a TGFß inhibitor (TGFßi) is a factor in some gastric submerged organoid 
preparations. For example Bartfeld et al. add 10µM to complete growth medium and show 
regular spherical organoid growth [68]. Therefore addition of a TGFßi was trialled.  
 
Organoids were cultured for six days and imaged through brightfield microscopy to see the 
impact of TGFßi in the media. TGFßi was added to complete growth media on day 0 and 
then continuously for all media changes (every 3 days) and compared to the same complete 
growth media without TGFßi, also changed every three days. Figure 17 is a representative 
organoid image from each treatment group on day 2 and day 6 of the assay. The organoids 
grown in regular growth medium have a normal phenotype on day 3 with a transparent 
spherical structure, however by day 6 these organoids have had a complete phenotype 
change. Organoids in normal media on day 6  adhere to the base of the growth plate, have 
lost their spherical structure, display budding growths, and are releasing cells outwards into 
the Matrigel, indicative of an EMT phenotype(Figure 17). Comparatively the organoids 
grown in TGFßi containing growth medium display normal spherical structure on both day 2 
and day 6. The organoids have normal growth rates and have no signs of death (granulation, 
disintegration, blackening)(Figure 17). Therefore all submerged organoid complete growth 
media will now contain TGFßi at 2µM concentration. This avoids the risk of TGFß in the 
Matrigel causing EMT and creating organoids that are no longer representative of the in vivo 
gastric system, and therefore not a relevant model for drug screening. TGFßi addition to 
growth medium maintains spherical gastric organoids which are appropriate for the 
modelling of HDGC.  
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Figure 17: Submerged organoids treated with and without TGFß inhibitor.  
Top: Submerged organoids grown in complete growth media, on day three and day six. Can 
see the EMT-like phenotype on day 6. Bottom: Submerged organoids grown in complete 
growth medium containing TGFß inhibitor. On both day three and day six, a healthy 
spherical morphology and normal growth is seen on both days.  
 
 
4.3.2. Seeding density analysis 
It was necessary for future drug assays in the submerged model to be completed within 96 
well cell culture plates to allow for multiple concentrations of drugs to be tested at once, 
similarly to 2D cell culture. However, submerged organoids had previously only been grown 
in 24 well plates in our laboratory. Therefore, an analysis of seeding density was done to find 
the optimum number of organoids that could be grown per well.  
Rather than a dome of Matrigel in the centre of the well, as done in 24 well plates,  96 well 
plates have the entire base of the well coated in Matrigel that the organoids grow within. The 
submerged organoids were seeded as single cells, as this allows accurate seeding as cells are 
able to be counted, and similar size organoids all originate from one cell. Previous data from 
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our laboratory has shown that the lower the seeding density the more variation in organoid 
number, so the highest number of submerged organoid cells seeded with minimal organoid 
degradation was wanted.  
 
In Figure 18, it is clear that a seeding density of 5000 single cells per well is too high and 
overcrowding is having an effect on organoid viability. By day four, organoids are showing 
signs of death, the organoids are darkening which indicates necrotic cells and the growth rate 
is slow as organoids look a similar size to that of day 2 in culture. There are also some 
organoids which have disintegrated (Figure 18). In comparison, a seeding density of 1000 
cells has organoids which are displaying no signs of death. On day 4 of culture they have a 
normal growth rate, a clear lumen free of necrotic cells, and the outer border of cells is intact. 
Therefore a seeding density of 1000 cells was taken through into the drug assay. At this 
density, there are enough organoids growing to reduce effect of variability, they display a 




Figure 18: Representative images of submerged organoid seeding density analysis.   
Submerged organoids seeded at different densities to optimise drug assay. Top- 5000 cells 
per well, day four showing dark organoids with very little growth. Bottom- 1000 cells per 
well, day four displaying healthy submerged organoids.     
 
4.3.3 DMSO toxicity 
Finding the concentration of DMSO that is toxic to the submerged organoids was the next 
step in the optimisation of the drug assay. Drug compounds and endoxifen are reconstituted 
in DMSO, therefore it is essential to know at what concentration of DMSO organoid viability 
is affected. Submerged organoids were seeded at the optimal 1000 cells per well and treated 
with increasing concentrations of DMSO and left for 48 hours. Viability of organoids was 
tested using the Alamarblue assay and read on the CLARIOstar. All concentrations below 
0.2% DMSO had similar viability, between 6-8 thousand fluorescence intensity , indicating 
very little impact of DMSO on the organoids (Figure 19). The concentration of DMSO which 
is added for each drugging assay is normally below 0.05%, therefore this data shows that 
there should be very little impact on the organoids from the 0.05% DMSO the drugs are 
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reconstituted in; toxicity should not be present until concentrations greater than 0.2% (Figure 
19). There was variability in this data so replicates need to be done. It is also essential that 
this DMSO toxicity is also tested in induced CDH1 knockout organoids, but this could not be 
completed for this thesis due to time constraints.  
 
 
Figure 19: Submerged organoid DMSO toxicity assay.  
Triplicate technical replicates for each concentration of DMSO. Viability is a normalised 
total fluorescence, analysed through AlamarBlue assay, read through the CLARIOstar. 
Similar viability for concentrations of DMSO 0.01%-0.2%. Toxicity only seen at the DMSO 
concentration of 10%.  
 
4.3.4 Preliminary submerged model drug assay  
A pilot drugging experiment was carried out to identify any other issues that may need to be 
optimised. Mocetinostat was used as it showed the most promising SL effect in both the NCI-




Submerged organoids were seeded in Matrigel at 1000 single cells per well in a 96 well plate. 
Organoid CDH1 knockout was induced after 24 hours, and then after a further 24 hours 
Mocetinostat was added at increasing concentrations - 1.25 µM, 2.5 µM, 5 µM and a DMSO 
control. Organoids were treated with Mocetinostat for 48 hours, and then stained with 
AlamarBlue and viability read as normalised total fluorescence, on the CLARIOstar plate 
reader. Results were in triplicate for each concentration. Columns in the bar graph (Figure 
20) are an average normalised to DMSO. The 2.5 µM concentration of Mocetinostat showed 
a promising differential trend, with the wildtype CDH1+/+ maintaining viability same as the 
DMSO control (Figure 20). In contrast the CDH1-/- organoids had a greater than 20% 
decrease in viability. Although more replicates will need to be done to validate this result, 
this data is further suggestive of CDH1-/- organoids being more sensitive to Mocetinostat than 
WT organoids (Figure 20). This assay is also still in development and further changes are 
being made to make results obtained more accurate (see discussion for further detail). 
 
Figure 20: Submerged organoids pilot drug assay with Mocetinostat   
Green: WT CDH1+/+, Grey: KO CDH1-/-. AlamarBlue viability assay of submerged organoids 
treated with Mocetinostat at a range of concentrations normalised to DMSO. Error bars are 
standard error.   
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4.4. Concluding remarks  
Synthetic lethal compounds have been identified and validated in the three models in this 
project. Firstly in the NCI-N87 drug screen, all compounds exhibited an SL response, with 
CDH1-/- cells having consistent lower viability than the WT counterparts (Figure 7-11). 
Atorvastatin showed a synthetic lethal trend at higher concentrations, (Figure 7) but no 
significant differential in viability between CDH1+/+ and CDH1-/- cells was observed. Of all 
the compounds, Mocetinostat exhibited the greatest SL effect, as at every concentration there 
was a significant decrease in viability of the CDH1-/- cells compared to WT.  
 
From this initial model, Vorinostat and Mocetinostat were then validated in an ALI organoid 
model. Results from the ALI drug assay were not conclusive due to limitations in the drug 
screening protocol. However Mocetinostat still displayed a difference in viability between 
CDH1-/- and CDH1+/+ organoids, indicative of a possible SL trend.  
 
The optimisation of the submerged model was successful, allowing for a pilot drug screen 
with Mocetinostat to be completed. The SL trend seen in previous models was again present, 
where CDH1-/- organoids displayed a lower viability compared to CDH1+/+ when treated with 
Mocetinostat. Through analysis of all three models together, this project has successfully 
identified Mocetinostat as a potential synthetic lethal chemopreventative compound for the 
treatment of HDGC. 
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Chapter 5: Discussion  
5.1 Identification of SL compounds  
The NCI-N87 cell culture model, ALI organoid model and the submerged organoid model, 
have been useful tools in this project for the identification of synthetic lethal compounds 
which selectively inhibit CDH1-/- cells. Compounds tested in this project, Atorvastatin, 
Entinostat, Pracinostat, Vorinostat and Mocetinostat were chosen as they were identified in 
the original known drug screen carried out in our laboratory [47]. From the preliminary NCI-
N87 high-throughput screen of these five compounds, data was used to decide which 
compounds to investigate further in the organoid models. This was based on greatest SL 
effect and analysis of current clinical trial data.   
 
5.1.1 Vorinostat  
Vorinostat is a pan-HDACi which has been FDA approved for the treatment of cutaneous T-
cell lymphoma (CTCL) [61]. Similarly to Mocetinostat, adverse effects of Vorinostat 
described in section 1.3.1.2, are able to be therapeutically managed so the drug has minimal 
impact on the patient.  
 
Initial testing in the NCI-N87 model of HDGC, Vorinostat showed a statistically significant 
synthetic lethal differential effect in CDH1-/- cells over the CDH1+/+ cells at a concentration of 
1.25 µM. Other concentrations of Vorinostat displayed a synthetic lethal trend with CDH1-/- 
cells consistently having a lower viability compared to the CDH1+/+ cells. Vorinostat was 
chosen for testing in the ALI organoid model, due to the FDA approval status, and low risk  
of severe adverse effects. This prior FDA approval in CTCL would allow for a quicker 
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pipeline for the FDA approval of Vorinostat for any other cancer type, for example for the 
treatment of HDGC.  
 
Vorinostat was further validated in the ALI organoid model for the drug-induced selective 
inhibition of CDH1-/-  cells. The data shows no SL effect for Vorinostat at 5 µM with the 
phenotype (Figure 12B) and change in growth being equivalent to that of the DMSO control 
(Figure 13). A higher concentration of Vorinostat may need to be tested to replicate the SL 
effect seen in the cell culture model to a 3D model. The variability in the ALI model meant 
that area change data had a very widespread distribution and therefore the effect or lack of 
effect of the drug is not easily understood from initial replicates. Secondly since the ALI 
model is a low throughput model, multiple concentrations of drug were not able to be tested 
at once. These limitations were resolved through the submerged model, discussed further 
below.  
 
Previous research has shown that Vorinostat treatment upregulates E-cadherin expression and 
is protective in cancer development. While this is not a mechanism for the synthetic lethal 
effect seen, it may be protective of development of HDGC. The singular functional CDH1 
gene that mutation carriers have could be upregulated through Vorinostat treatment, to 
prevent the formation of cancerous phenotypes forming [76].  
 
5.1.2. Mocetinostat  
Mocetinostat is an HDACi which specifically inhibits class 1 and 4 HDAC’s. Through 
current clinical trial data, it has been shown that Mocetinostat does have certain adverse 
effects, as described in section 1.3.1.2., however these have been able to be minimised 
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therapeutically [59]. FDA approval exists for Mocetinostat as treatment for diffuse large cell 
B lymphoma [60]. 
 
Mocetinostat demonstrated a significant SL effect at every concentration tested, with 
decreased viability in CDH1-/- cells relative to CDH1+/+ cells  (Figure 10). This data for 
Mocetinostat is particularly encouraging because at the three lowest concentrations, CDH1+/+ 
cell viability is unaffected, while CDH1-/- cell viability drops to 70% viable. Mocetinostat 
concentrations demonstrating no impact on viability of the CDH1+/+cells represents 
unaffected ‘healthy’ cells. This is promising for a potential HDGC therapy, because treatment 
with minimal impact on the patient is preferable. The significant SL effect observed across 
multiple drug concentrations was the reason that Mocetinostat was selected for further 
validation in the other HDGC models in this project.  
 
In contrast to Vorinostat, Mocetinostat did show a difference in viability in the ALI organoid 
model, with signs of organoid death compared to the ‘healthy phenotype of the DMSO 
negative control organoids (Figure 12). The data for change in growth for organoids treated 
with Mocetinostat was also suggestive of a minor differential effect, with a slight inhibition 
of growth in CDH1-/- organoids compared to CDH1+/+ organoids. This data was not 
statistically significant and only suggestive of a SL response, showing more investigation 
needs to occur in other models.  Although both drugs were tested in triplicate, with each 
replicate containing at least three organoids, the data is extremely variable, indicated by the 
large standard error of the mean (Figure 13).  
 
Finally, Mocetinostat was trialled in the submerged organoid model. This drug assay was a 
pilot assay, because the submerged model is not yet fully optimised, however, a synthetic 
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lethal effect was seen in this singular replicate. At a concentration of 2.5 µM Mocetinostat, 
the CDH1+/+ organoids had 100% viability compared to the DMSO control, while the CDH1-
/- organoids dropped in viability to around 70% compared to the DMSO control. This pilot 
assay with Mocetinostat provided important information for the further development of the 
viability assay in the submerged organoid model. Once optimisation is complete, the 
submerged model will be used for future drug screening of potential SL compounds.  
 
Mocetinostat displayed selective inhibition of CDH1-/- cells across three different models of 
HDGC.  This is hypothesised to be due to Mocetinostat specifically inhibiting HDAC1, 
which is overexpressed in 68% of gastric cancers [56]. Vorinostat and Pracinostat are pan-
HDAC inhibitors, meaning they inhibit all classes of HDAC. This nonspecific inhibition 
likely effects the viability of both the CDH1+/+ cells and CDH1-/- cells, leading to a decreased 
SL effect [52]. Mocetinostat has also been shown to increase E-cadherin and B-catenin 
localisation to the membrane, which reduces the EMT phenotype. This may be another 
potential mechanism of Mocetinostat inhibiting in cancer formation, as cells are inhibited 
from undergoing EMT [77].  
 
5.2. Limitations  
5.2.1 NCI-N87 model 
One limitation of the NCI-N87 drug screening protocol used is the measurement of cell 
viability. Viability was measured through total nuclei counting, Hoechst stains the nuclei, 
which can then be counted and a differential nuclei count between CDH1+/+ cells and CDH1-/- 
cells observed. This method does not establish whether the difference in cell number is due to 
a cytostatic or cytotoxic effect. Hoechst stain is able to diffuse across cell membranes, 
staining both live and dead cells and all are counted for the final nuclei count [78]. Drug 
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treatment could cause a decrease in CDH1-/- cell number through a cytostatic mechanism, 
where cells are live but inhibited from completing the cell cycle and unable to replicate. The 
other option is that drug treatment has a cytotoxic effect by killing CDH1-/- cells. The 
mechanism of drug action could be either cytostatic or cytotoxic, as Hoechst is not able to 
differentiate between the two. For a potential chemopreventative treatment, a drug which 
inhibits CDH1-/- cell growth needs to be cytotoxic, to completely eliminate cancer cells, and 
thus any risk of HDGC. To address this, apoptosis assays need to be carried out with the 
drugs used in this study prior to further pre-clinical development (see future directions). 
 
5.2.2. ALI model 
 
 The ALI model is designed to be similar to the in vivo gastric gland. Organoids are grown at 
an air-liquid interface within a collagen matrix, facilitating growth of 3D structures. Co-
cultures with MFB represents the in vivo stromal cells.  Resulting organoids are made up of 
all lineages of gastric cells. All of these features make the ALI model theoretically suitable as 
a pre-clinical model. However, in practice, these characteristics are also what make the ALI 
model variable and not an ideal model for drug screening. 
 
Several sources of variability were observed in ALI organoids. Firstly, variability in the size 
of the organoids in every well was problematic.  This variation in size is introduced due to 
the fragmentation of gastric tissue in the preparation of organoids. Gastric tissue is 
mechanically broken down with scissors, and although the protocol is strictly followed, tissue 
of varying sizes will always be produced. When seeded, the larger pieces of tissue generally 
form larger organoids, while smaller tissue fragments form smaller organoids. Secondly, 
there was variation in the number of organoids per well. This is introduced as the number of 
tissue pieces cannot be counted. It is assumed that they are evenly distributed throughout the 
collagen preparation and this mixture is then evenly distributed across each well. This leads 
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to the variability in the number of organoids per well, from 3 – 20 growing in a single 
experiment preparation. Lastly, variation is introduced by certain tissues developing classic 
organoids and others forming halo organoids. This may be due to differences in stem cell 
abundance across different pieces of tissue. Tissue containing more stem cells is likely able to 
develop into a true organoid, with limited stem cell populations forming halo organoids. The 
halo organoid growth may also be due to the myofibroblasts surrounding the piece of tissue 
not releasing enough growth factors to stimulate organoid growth. Halo organoids are not 
representative of the in vivo gastric gland, therefore they cannot be analysed alongside true 
organoids to determine drug effect on growth. A separate analysis of halo organoids was 
performed in this project (Figure 16). Overall for the ALI model to be an effective model for 
drug screening, it requires tissue pieces to be of uniform size, with an equal concentration of 
tissue placed into each well, and most of these equal sized pieces of tissue to form into true 
organoids. These factors cannot be controlled using the current protocol, therefore this model 
is not suitable for routine drug screening in its current format. However it does provide a 
useful model for the visualisation of CDH1-null cells in HDGC, as it is the most 
representative model of the in vivo gastric gland. After drug treatment, confocal microscopy 
of the ALI organoids remains an important step in understanding the impact of drug on 
cellular structure, behaviour and how the overall organoid structure is impacted.  
 
5.2.3 Submerged 
The submerged model was developed in the Clevers laboratory [65, 68], and is being adapted 
in the Cancer Genetics Laboratory by Tom Brew. The organoids grown in the laboratory 
have similar growth and phenotype to those seen in the literature.   
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Optimisation of the submerged model started in an attempt to circumvent some of the 
limitations previously discussed with the ALI model. For example, the ALI model is low 
throughput as it requires fresh murine gastric tissue for each preparation. The submerged 
model allows for organoids to be propagated, with murine gastric tissue only being required 
for the initial preparation. This makes submerged organoids a medium throughput model 
which is easier to use for the preparation of drug screening assays. Secondly the co-culture 
with myofibroblasts is no longer required, as the growth factors added to the complete culture 
medium stimulate growth of the organoids (Table 2). For each ALI drug assay preparation, 
14 confluent 75 mL cell culture flasks of myofibroblasts were required to be added to the 
collagen. The addition of growth factors to the culture medium is a less labour intensive 
process, another factor that makes the submerged model higher throughput compared to the 
ALI model.  
 
As discussed, the variability in size, number and type of organoid in the ALI model is the 
major limitation of that model for drug screening. The submerged model is able to avoid all 
of these issues. Submerged organoids are seeded in the Matrigel as single cells and all follow 
a similar growth pattern, so at day six are all a similar size, this can be seen in the seeding 
density analysis (Figure 18). As submerged organoids are propagated as single cells, they are 
also able to be counted on the LUNA automated cell counter, so the concentration of cells in 
the volume of Matrigel is known and accurate seeding occurs (Figure 18). Lastly, as tissue is 
only used for the initial preparation, halo organoids are not present in the submerged model. 
However, the EMT phenotype organoids were an uncharacterised structure that was not-
representative of the in vivo environment, although these EMT like structures were able to be 
inhibited with the TGFßi. treatment (Figure 17). The submerged model is therefore better for 
drug screening, as it is far less variable that the ALI.  
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5.3 Future directions  
A Fluorescence Activated Cell Sorting (FACS) apoptosis assay could be used to distinguish 
between a cytotoxic or cytostatic effect upon drug treatment. The FACS assay uses 
fluorescent markers to distinguish between live, early apoptotic and late apoptotic cells. The 
first marker, Annexin-V-FITC protein binds to pre-apoptotic membrane proteins which are 
present on the outside of a cell about to undergo apoptosis [79]. The second marker 
propidium iodide selectively diffuses into apoptotic or necrotic cells due to a compromised 
cell membrane. FACS separates the sample into three populations. Viable cells are negative 
for both markers, early apoptotic cells are only Annexin-V-FITC positive, and late apoptotic 
cells are positive for both Annexin-V-FITC and Propidium iodide. A cytotoxic drug will 
result in pre-apoptotic and late-apoptotic cell population, whereas a cytostatic drug will 
maintain viable cells. This would allow for differentiation between cytostatic and cytotoxic 
compounds [79] 
 
The current analysis of organoid viability is done through brightfield imaging and area 
measurement. This analysis is therefore done using one 2D image of a 3D spherical structure. 
This method just analyses size, however organoids are viable growths, that require a more in 
depth and accurate measure of viability. The representative images of the ALI organoids 
show this issue with all displaying similar growth rates, however some are much unhealthier 
looking than the DMSO controls (Appendix 1, 2 & 3). A growth rate analysis may notice 
very little change, but a viability assay looks into the more accurate measure of cells which 
are actually viable. A viability assay would be able to distinguish between organoids made up 
of viable cells compared to necrotic cells, regardless of size of the organoid, and be a better 
measure of any SL effect.  
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Another future direction for this model is to look at the long term impacts on the organoids of 
drug treatment. The 12 day analysis of the halo organoid data showed that long term 
Mocetinostat had a strong SL effect (Figure 13). This long term analysis could be applied to 
the ALI true organoids, which have been shown to be able to be cultured for a year [80]. This 
could potentially have a more definitive selective inhibition of CDH1-/- organoids, especially 
if multiple doses of drug were added, similarly to a treatment scheme for how patients would 
take the medication as chemoprevention. It would be interesting to complete an assay with 
long term multiple dosage of organoids to see if CDH1+/+ organoids would remain viable 
while CDH1-/- organoids slowly disintegrate, similarly to the halo organoids (Figure 16).  
 
TGFßi. treatment removed the EMT phenotype organoids from the preparation, however for 
drug screening assays it may interfere with the drug treatments, as the inhibitor is currently 
added with every new media addition every three days. A future experiment looking into 
adding the TGFßi on only day 0 when the organoids are seeded, to see whether one dose is 
enough to inhibit the EMT phenotype would be valuable. It could then be confirmed that any 
selective decrease in viability of CDH1-/- organoids is due to the compound being tested 
alone, not a combination of the compound and the TGFßi.  
 
Secondly, the DMSO toxicity test of the submerged organoids needs to be further validated. 
The preliminary analysis completed in this project demonstrated that the CDH1+/+ organoids 
did not experience a significant decrease in viability in concentrations of DMSO below 0.2%. 
Further investigation into what concentration of DMSO is the maximum before toxicity 
occurs needs to be done, and a replicate of this experiment with CDH1-/- organoids is 
essential. Following on from the assay optimisation, the submerged organoid model will be 
utilised for medium throughput SL drug screening in a 3D organoid model. Initially with 
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more replicates of Mocetinostat, as the pilot study in this model, will be done to confirm the 
SL effect seen due to Mocetinostat in the submerged organoids.  
 
5.4. Clinical relevance  
A chemopreventative compound for the treatment of HDGC is necessary as the current 
optimal treatment is prophylactic gastrectomy. Gastrectomy has both physical and 
psychological impacts on patients and is also overtreatment in cases where there is no family 
history of gastric cancer but a CDH1 mutation present. A chemopreventative compound will 
aim to target CDH1 negative cells to reduce the risk of HDGC development, and therefore 
the need for prophylactic gastrectomy.  
The drugs chosen for this project were specifically assessed for low toxicity and minimal 
adverse effects to minimise the impact on patients. As a potential preventative therapy, 
carriers of CDH1 mutations do not have gastric cancer and are physically healthy, therefore a 
chemopreventative drug should not impact day to day life with severe adverse effects, and 
make carriers unwell, as that is not an improvement on the current treatment of prophylactic 
gastrectomy. For example the HDACi Mocetinostat, FDA approval exists for this compound 
indicating low levels of adverse effects and a pre-existing pipeline for the potential FDA 
approval for Mocetinostat HDGC treatment. Adverse effects associated with HDACi are 
fatigue, nausea and diarrhoea, which are all effects that can be managed therapeutically. Drug 
data was analysed for each compound to find concentrations where CDH1+/+ cells exhibit 
close to 100% viability and CDH1-/- cell viability was significantly affected. As at significant 
concentrations like this, where the CDH1+/+  cells represent healthy gastric cells, which are 
unaffected, leading to minimal effects on the patient.  
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5.5 Concluding statement  
In conclusion, this project has successfully identified synthetic lethal compounds which 
selectively inhibit CDH1-/- cells. All compounds tested in the NCI-N87 cell culture model 
displayed evidence of synthetic lethality, with HDACi having the most significant selective 
CDH1-/- cell inhibition. Vorinostat and Mocetinostat, were further validated in an ALI 
organoid model. Results from the ALI drug assay were inconclusive due to limitations in the 
drug screening protocol. This lead to the optimisation of an alternative organoid model, 
referred to as the submerged organoid model, and a pilot drug assay in this model. Results 
from each of these model systems has successfully identified Mocetinostat as a potential 
chemopreventative compound for the treatment of HDGC. In future, further validation of 
Mocetinostat will need to be completed, in the new submerged organoid model and then in 
HDGC mouse models, to provide basis for a clinical trial of a chemopreventative compound 
for HDGC. The importance of a chemopreventative option is especially important in NZ. As 
the proportion of CDH1-/-  mutations in the Māori population is three to five fold higher to 
that of the NZ European population [26]. A treatment option is necessary that eliminates the 



















Appendix 1: Representative brightfield images of WT and CDH1 KO ALI organoids 
treated with the DMSO control. 






Appendix 1: Representative brightfield images of WT and CDH1 KO ALI organoids 
treated with 5µM Vorinostat.  





Appendix 2: Representative brightfield images of WT and CDH1 KO ALI organoids 
treated with the 0.63 µM Mocetinostat.  
Organoids shown on day 2 and day 6. All display signs of death by day 6. Organoids are 
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